Hong Kong PR

重點成果- 年內，集團共有4個創新產品獲NMPA批准上市，分別為賽坦欣(R)（庫莫西利膠囊）、聖赫途(R)（宗艾替尼片）、普坦寧(R)（美洛昔康注射液(II)）和安啟新(R)（注射用重組人凝血因子VIIa N01）。- 2025年，集團創新產品收入達到人民幣152.2億元，同比增長26.2%。此外，集團已在上海、南京、北京、廣州等地建立多個研發中心，並成功構建了涵蓋小分子、蛋白降解劑、siRNA、單抗／雙抗、抗體偶聯藥物（ADC）、吸入製劑、透皮貼劑等領域的多元化創新技術平台。- 截至2025年12月31日，集團共有39個腫瘤領域、10個肝病╱心血管代謝領域、14個呼吸╱自免領域、和6個外科╱鎮痛領域的創新候選藥物處於臨床申請及以上開發階段。其中，1個腫瘤領域、2個外科╱鎮痛領域產品處在上市申請階段；13個腫瘤領域、1個肝病╱心血管代謝領域、5個呼吸╱自免領域、1個外科╱鎮痛領域的創新候選藥物處於臨床III期，9個腫瘤領域、6個肝病╱心血管代謝領域、5個呼吸╱自免領域、2個外科╱鎮痛領域的創新候選藥物處於臨床II期，另有16個腫瘤領域、3個肝病╱心血管代謝領域、4個呼吸╱自免領域、1個外科╱鎮痛領域的創新候選藥物處於臨床I期。- 福可維(R)（鹽酸安羅替尼膠囊）是一款新型小分子多靶點酪氨酸激酶抑制劑，目前已獲批10項適應症，其一線非鱗狀非小細胞肺癌、一線胰腺癌等多項新適應症正在開展III期臨床研究，預計未來兩年將逐步遞交上市申請。- 2023-2025年，集團共有7款腫瘤領域的國家1類創新藥獲批上市，分別為：賽坦欣(R)（庫莫西利膠囊）、聖赫途(R)（宗艾替尼片）、億立舒(R)（艾貝格司亭α注射液）、安得衛(R)（貝莫蘇拜單抗注射液）、安柏尼(R)（富馬酸安奈克替尼膠囊）、安洛晴(R)（枸櫞酸依奉阿克膠囊）和安方寧(R)（格索雷塞片）；以及4款腫瘤領域的生物類似藥獲批上市，分別為：安倍斯(R)（貝伐珠單抗注射液）、得利妥(R)（利妥昔單抗注射液）、賽妥(R)（注射用曲妥珠單抗）和帕樂坦(R)（帕妥珠單抗注射液）。該等產品在2025年快速放量，成為集團收入增長的重要貢獻品種。- 天晴甘美(R)（異甘草酸鎂注射液）是第四代甘草酸製劑，目前已獲批3個適應症。集團年內著力加強學術推廣，透過各層級的學術會議增強了醫生覆蓋和專家認可，同時大力發掘新患者拓展新市場，並積極推進回顧性研究，為其臨床使用提供更多的學術證據。- TQC3721（PDE3／4抑制劑）是一款PDE3／4雙重抑制劑，目前正在中國開展III期臨床試驗，用於治療中重度慢性阻塞性肺病（COPD）。集團正在開發TQC3721的多種劑型：吸入用混懸液位於III期臨床階段，吸入粉霧劑位於II期臨床階段，有望透過多種劑型進一步提升患者的依從性。 - 澤普思(R)／得百安(R)（氟比洛芬凝膠貼膏）是中國首個獲批上市的國產凝膠貼膏，連續多年蟬聯外用鎮痛市場份額第一位。集團聚焦高潛力地區開發，深入拓展市場覆蓋，並逐步擴大產能以滿足市場的旺盛需求，推動澤普思／得百安銷售額持續快速增長。集團開發的第二代氟比洛芬貼劑預計將在年內獲批上市，透過劑型升級，二代產品可顯著提高藥物透皮吸收度，增強貼膏粘附性，從而提升患者的依從性。 香港, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 中國領先的創新研發驅動型醫藥集團-中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）公佈截至2025年12月31日止12個月（「年內」）之經審核財務業績。年內，集團收入增長約10.3%至約318.3億元（人民幣，下同）。來自持續經營業務之歸屬於母持有者盈利（財務報表所示）約23.4億元，按年增長約22.0%。來自持續經營業務之歸屬於母公司持有者盈利計算之每股基本盈利約人民幣13.02分，較去年增加約24.0%。歸屬於母公司持有者之基本溢利約45.4億元，按年增長約31.4%。集團流動資金保持充裕，年內有計入流動資產之現金及銀行結餘約121.8億元、計入非流動資產之銀行存款約102.5億元，理財管理產品總額約105.6億元，資金儲備總額約329.9億元。董事會建議派發末期股息每股5港仙（2024年：4港仙），連同已派發中期股息每股5港仙，全年合共派發股息每股10港仙（2024年：7港仙）。銷售：創新引領，銷售動能持續釋放年內，集團持續加大投入以提升研發質效，研發實力顯著增強，驅動銷售收入持續增長，成果豐碩。年內，創新產品之收入同比增加26.2%，達約152.2億元。至於分治療領域，抗腫瘤用藥之收入同比增加22.8%，達約131.8億元，佔集團收入約41.4%。外科／鎮痛用藥之收入同比增加12.8%，達約50.3億元，佔集團收入約15.8%。腫瘤領域，集團全面佈局非小細胞肺癌領域，覆蓋多種分型的全線治療，福可維(R)（鹽酸安羅替尼膠囊）已獲批10項適應症，多項新適應症處於上市申請或III期臨床階段，其聯合療法在肺癌治療中展現出優效。2023年至2025年間，集團共有7款腫瘤領域的國家1類創新藥以及4款腫瘤領域的生物類似藥獲批上市，該等產品在2025年快速放量，成為集團收入增長的重要貢獻品種。於外科╱鎮痛領域，澤普思(R)／得百安(R)（氟比洛芬凝膠貼膏）連續多年蟬聯外用鎮痛市場份額第一位，第二代氟比洛芬貼劑預計將在年內獲批上市，有望透過劑型升級鞏固市場領先地位。同時，中國首款一日一次長效鎮痛NSAIDs注射液普坦寧(R)（美洛昔康注射液（II））已於2025年5月獲得NMPA和FDA的上市批准，並已被新增納入2025年國家醫保藥品目錄，有望成為集團鎮痛領域的又一款重磅產品。研發：技術築基，研發質效顯著提升研發創新始終是集團的核心驅動力，集團目前已在上海、南京、北京、廣州等地建立多個研發中心，並成功構建了涵蓋小分子、蛋白降解劑、siRNA、單抗／雙抗、抗體偶聯藥物（ADC）、吸入製劑、透皮貼劑等領域的多元化創新技術平台。截至二零二五年十二月三十一日止年度，研發總投入約人民幣63.2億元，佔集團收入約19.8%。集團亦重視保護知識產權，積極申報各項專利，以提高核心競爭力。年內，集團提交專利申請1,167項、獲得專利授權273項。截至年末，集團累計有效專利申請達5,724項，累計有效專利授權達2,120項。展望：聚焦創新，堅定推進國際化戰略展望未來，集團將繼續聚焦創新，深耕腫瘤、肝病／心血管代謝、呼吸／自免、外科／鎮痛四大核心治療領域，以AI深度賦能研發全流程，持續強化創新研發能力推動業績穩步增長。預計未來三年（2026-2028年），集團創新管線將迎來新一輪爆發式增長，預計近20款國家1類創新藥有望獲批上市，涵蓋多款具備全球同類首創 (FIC) ／同類最佳 (BIC) 潛力的重磅產品。預計至2028年底，集團上市創新產品總數將達到近40款，成為驅動業績增長的核心引擎。同時，集團堅定推進國際化戰略。2026年2月，集團宣佈授予Sanofi在全球範圍內開發、生產及商業化羅伐昔替尼的獨家許可，並有權獲得最高15.3億美元的付款，以及基於羅伐昔替尼年度淨銷售額的高達雙位數的銷售提成。未來，對外授權合作將成為集團的又一重要收入來源，持續為業績增長注入強勁新動能，正式開啟以國際化收入為支撐的第二增長曲線。此外，集團始終秉持「合作共贏」理念，著力構建開放多元的創新生態體系。透過與全球頂尖藥企、生物科技公司及科研機構的深度合作，集團正加速彙聚全球優質資源，推動創新成果的共創共享，持續鞏固市場領導地位。透過整合禮新醫藥、赫吉亞等優質資源，集團在腫瘤免疫及siRNA等前沿賽道的研發實力顯著增強。未來，集團將繼續以自主研發與戰略合作雙引擎驅動創新，以國際化加速發展，向世界級創新醫藥企業的戰略目標穩步邁進。有關集團本年度詳細業績資料，請參閱集團上載至香港聯合交易所及官網之正式公告。有關中國生物製藥有限公司（股票編號：1177）中國生物製藥，連同其附屬公司，是中國領先的創新研究和研發驅動型醫藥集團，業務覆蓋醫藥研發平台、智慧化生產和強大銷售體系全產業鏈。產品包括多種生物藥和化學藥，在腫瘤、肝病／心血管代謝、呼吸／自免、外科／鎮痛四大治療領域處於優勢地位。公司於2000年在香港聯交所上市，2013年入選MSCI全球標準指數之中國指數成分股；2018年入選恒生指數成分股；2020年入選恒生滬深港通生物科技50指數成分股、恒生中國(香港上市)25指數。中國生物製藥連續七年榮登美國權威雜誌《製藥經理人》發佈的「全球製藥企業TOP50」，連續三年獲評《福布斯》(亞洲) 「亞太最佳公司50強」。有關中國生物製藥的進一步資料，請瀏覽: www.sbpgroup.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

West Palm Beach, FL, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA) founded in 1890, today announced the launch of its Global Polo Shirt Campaign, An Icon Born from the Game. The global campaign is a powerful tribute to the iconic polo shirt's authentic sports origins and its evolution into one of the world's most enduring style essentials.U.S. Polo Assn. Global Brand Ambassador, 6-goal American professional polo player Nico Escobar takes in the game atop his equine partner, wearing polo whites and a classic navy U.S. Polo Assn. polo shirt, An Icon Born from the GameU.S. Polo Assn. models in polo shirts at the Spring-Summer 2026 Global Collection Photoshoot in Charleston, South Carolina‘The Polo Shirt: An Icon Born From the Game' campaign imagery featuring U.S. Polo Assn. modelsThe polo shirt's beginning was born on the polo fields, shaped by motion, competition, and the spirit of the game for which it was named. From its earliest days, the polo shirt was designed with purpose, worn by players seeking performance on the polo fields. Today, U.S. Polo Assn. celebrates this timeless favorite, not just as a fashion item, but as an icon born from sport and carried forward through generations of players and consumers all over the world.The polo shirt is one of the most iconic essentials dating back over 100 years, notable for its unique fusion of sport and style. Originally designed with breathable pique knit, a soft collar, and lightweight construction to meet the demands of competitive sports, it has evolved into a timeless essential, suitable for casual elegance and leisurewear.The polo shirt traces its origins to polo players, where it was created out of necessity for the sport. Polo players modified long‑sleeved cotton shirts to better handle heat, movement, and wind while playing. These functional, sport‑driven adaptations represent the earliest form of what would become the polo shirt. In the early 20th century, polo players helped formalize these functional elements as the sport gained popularity, reinforcing the shirt's connection to the sport and its functional design.Over the years, the polo shirt became a cornerstone of casual sportswear around the world, symbolizing preppy style, luxury leisure culture, and contemporary athleisure, seamlessly transitioning from polo fields to college campuses and boardrooms. Its enduring adaptability is demonstrated by distinct reinventions across the decades; the ability to evolve has ensured the polo shirt's lasting relevance and cultural significance.As the official sports brand of the USPA, founded in 1890 and one of the oldest sports governing bodies in the United States, U.S. Polo Assn. occupies an authentic place in the history of the polo shirt."The polo shirt's DNA is deeply rooted in the inspirational sport that inspired it," said J. Michael Prince, President and CEO of USPA Global, the company that manages and markets the multi-billion-dollar, global U.S. Polo Assn. brand. "With An Icon Born from the Game, we're honoring a legacy that began on the field and continues to shape how polo players, sports fans, and consumers all over the world live, move, and express themselves today, and for future generations."An Icon Born from the Game reinforces that legacy by connecting the polo shirt's origins in the sport, while celebrating its place in modern culture."The polo shirt was designed for the game with a real purpose on the field, but it's also what I wear off the field to go out to dinner or hang out with friends and family," said Nico Escobar, U.S. Polo Assn. Global Brand Ambassador, 6-goal American professional polo player. "I love that U.S. Polo Assn. understands both the performance aspect and how the polo shirt fits into everyday life.""U.S. Polo Assn.'s authentic connection to the sport and the way it supports the game of polo around the world is why I wear it - both on the field and off," adds Escobar.Global Launch: An Icon Born from the GameLaunching globally across 190 countries in Spring 2026, An Icon Born from the Game will come to life through a coordinated, multi‑channel presence designed to make the U.S. Polo Assn. polo shirt unmistakably visible wherever consumers engage with the sport-inspired brand. In stores, dedicated polo shirt focus areas, including the brand's iconic polo walls, window displays, and visual merchandising moments, will highlight the full range of styles through bold color stories, clear categorization, and campaign signage anchored by the slogan.Across outdoor and print advertising, hero imagery shot on location brings the polo shirt back to the field, reinforcing its authentic connection to the sport, while digital and social media activations extend the story through short‑form content and global storytelling. Together, these touchpoints create a consistent, immersive expression of the polo shirt as a true icon rooted in sport but relevant to everyday life.Further, An Icon Born from the Game is launching around two of the sport's most important events in the United States - the prestigious USPA Gold Cup® and one of the most competitive tournaments in the world, the U.S. Open Polo Championship®, which concludes with the Championship Final on April 26."An Icon Born from the Game is about owning our truth and telling it boldly on a global scale," said Stefanie Coroalles, Vice President, Global Brand Marketing. "The Global Polo Shirt Campaign brings together heritage, product, and self-expression, showing how the polo shirt moves effortlessly from sport to everyday life.""This launch is a proud moment for us, one that brings our heritage to life in a way that feels modern, visible, and unmistakably U.S. Polo Assn.," adds Coroalles.Product Pillars: Play It Your Way"Every U.S. Polo Assn. polo shirt is designed with intention by balancing style, comfort, function, and authentic sport details," said Brian Kaminer, Senior Vice President, Brand and Product Development. "From heritage-inspired construction to modern performance fabrics, our U.S. Polo Assn. collections reflect how the polo shirt continues to evolve while staying true to its sports roots."The global polo shirt campaign showcases the versatility of the icon through five distinct expressions that give the consumer the opportunity to "Play It Your Way" when styling with the polo shirt.Play It Sporty is the polo shirt that carries the legacy of U.S. Polo Assn. in every stitch. Featuring authentic detailing, iconic branding, and sport-inspired elements, this timeless silhouette connects directly to the game that started it all. Official crests, classic cuts, and traditional design details celebrate the sport of polo's history and the brand's deep-rooted heritage.Play It Classic is the polo shirt for the moments that make up everyday life. Clean, comfortable, and easy to style, it's the go-to option when you want something that always works. Designed to be worn again and again, it fits seamlessly into any routine, whether casual, relaxed, or slightly dressed up.Play It in Motion with the performance polo shirt engineered for action. Advanced technical fabrics deliver moisture-wicking comfort, breathability, and stretch that moves with you throughout the day. Designed for polo players on the field or in life in motion, it balances durability and function with a sharp, modern look.Play It Bold is the fashion polo shirt built for self-expression. Defined by confidence and style, this version brings personality and freedom to a familiar icon. Worn casually or styled with intention, it shows how versatile the polo shirt can be when it's shaped by confidence and worn on an individual's own terms.Play It Elevated is the premium polo shirt made for moments that call for refinement. Crafted with elevated materials and thoughtful detailing, it offers a polished look without feeling formal. Clean lines and a thoughtful fit create a composed yet confident style that balances ease with sophistication.U.S. Polo Assn.'s seasonal polo shirts are offered across men's, women's, and kids' collections in an expansive range of fabrics, finishes, and colors - from classic neutrals to vibrant hues. Updated designs feature textured ribs, subtle patterns, and elevated construction details, finished with the brand's signature Double Horsemen logo - a mark of authenticity and a symbol of the sport.U.S. Polo Assn. continues to incorporate products aligned with its global sustainability program, USPA Life, reflecting the brand's commitment to responsible sourcing and long-term environmental initiatives. The USPA Life Polo Shirt, arriving in stores Spring 2027, builds on U.S. Polo Assn.'s most iconic style, designed with thoughtfully chosen, preferred materials that reflect the brand's commitment to improving the global footprint of this iconic staple. From 100% preferred cotton fabric to the finishing details like buttons and thread, each element has been selected to reduce impact while preserving the classic look, comfort, and quality customers expect from a U.S. Polo Assn. polo shirt.U.S. Polo Assn. apparel and accessories are available in U.S. Polo Assn. stores and online at uspoloassnglobal.com.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sportsin India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth and sports content. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.For Additional Information, Contact:Stacey Kovalsky - VP, Global PR and CommunicationsPhone +954.673.1331 - E-mail: skovalsky@uspagl.comKaela Drake - Senior PR and Comms SpecialistPhone +561.530.5300 - E-mail: kdrake@uspagl.comSOURCE: U.S. Polo Assn. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

佛羅里達州西棕櫚灘, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 由1890年成立的美國馬球協會（USPA）所授權的官方運動品牌 U.S. Polo Assn.，今日宣布推出全球馬球衫宣傳活動「源自賽場的經典」。這項全球性活動旨在向標誌性的馬球衫致敬，彰顯其純正的運動淵源，以及它如何演變為全球最歷久彌新的時尚經典之一。U.S. Polo Assn. 全球品牌大使、6級美國職業馬球選手尼科·埃斯科巴（Nico Escobar）身著馬球白裝與經典海軍藍 U.S. Polo Assn. 馬球衫，騎乘愛駒觀賽，展現「源自賽場的經典」精神U.S. Polo Assn. 模特兒身著馬球衫，於南卡羅來納州查爾斯頓參與 2026 春夏全球系列攝影「馬球衫：源自賽場的經典」宣傳影像，由 U.S. Polo Assn. 模特兒演繹Polo衫的起源可追溯至馬球場，其設計深受運動動作、競技精神以及這項賦予其名稱的運動所塑造。自問世之初，Polo衫便以實用為本，由追求賽場表現的球員們所穿著。時至今日，U.S. Polo Assn. 不僅將這款歷久不衰的經典視為時尚單品，更視其為源自運動、並由全球數代球員與消費者共同傳承的標誌性象徵。馬球衫是擁有逾百年歷史的最具代表性經典單品之一，以其獨特的運動與時尚融合而著稱。最初採用透氣的平紋針織面料、柔軟的領口及輕量結構，以滿足競技運動的需求；如今已演變為永恆的經典單品，既適合展現休閒優雅，亦是理想的生活休閒服飾。Polo衫的起源可追溯至馬球運動員，其誕生源於這項運動的實際需求。馬球運動員為在比賽中更好地應對高溫、動作與風勢，對長袖棉質襯衫進行了改良。這些以功能性為導向的運動改裝，正是日後Polo衫的雛形。20世紀初，隨著馬球運動日益普及，運動員們協助將這些功能性元素正式化，進一步鞏固了Polo衫與這項運動及其功能性設計之間的連結。多年來，馬球衫已成為全球休閒運動服飾的基石，象徵著學院風、奢華休閒文化與當代運動休閒風，從馬球場到大學校園，再到會議室，皆能無縫融入。數十年來，馬球衫歷經多次獨特的革新，展現出其持久的適應性；這種不斷演進的能力，確保了馬球衫歷久不衰的流行地位與文化意義。作為美國馬球協會（USPA）的官方運動品牌，U.S. Polo Assn. 佔據了馬球衫歷史中獨一無二的地位。USPA 成立於 1890 年，是美國歷史最悠久的體育管理機構之一。「馬球衫的基因深深植根於那項啟發它的鼓舞人心運動，」USPA Global 總裁兼執行長 J. Michael Prince 表示。該公司負責管理並推廣這個價值數十億美元的全球性 U.S. Polo Assn. 品牌。「透過『源自賽場的傳奇』系列，我們致敬這份始於球場的傳承，它持續塑造著全球馬球選手、運動迷及消費者當下的生活、行動與自我表達方式，並將影響未來的世代。」「源自賽場的傳奇」系列透過連結馬球衫與這項運動的淵源，同時彰顯其在現代文化中的地位，進而鞏固這份傳承。「這件馬球衫是專為比賽設計，在球場上確實有其實際用途，但它也是我場下外出用餐或與親友聚會時會穿的服裝，」U.S. Polo Assn. 全球品牌大使、6級美國職業馬球選手尼科·埃斯科巴（Nico Escobar）表示。「我很欣賞 U.S. Polo Assn. 既重視機能表現，也懂得如何讓馬球衫融入日常生活。」「U.S. Polo Assn. 與這項運動的真摯連結，以及它對全球馬球運動的支持，正是我無論在場上或場下都選擇穿著它的原因，」埃斯科巴補充道。全球發佈：「源自賽場的經典」「源自賽場的經典」系列將於2026年春季在全球190個國家同步上市，透過協調一致的多渠道佈局，讓美國馬球協會的馬球衫在消費者接觸這個運動靈感品牌的任何場合都清晰可見。在實體店鋪中，專門的馬球衫展示區——包括品牌標誌性的馬球衫牆、櫥窗陳列及視覺 merchandising 亮點——將透過大膽的色彩故事、清晰的品類劃分，以及以標語為核心的活動標識，全面呈現各類款式。無論是戶外廣告還是平面廣告，現場拍攝的主視覺影像將馬球衫帶回球場，強化其與這項運動的真實連結；而數位與社群媒體的推廣活動，則透過短片內容與全球敘事延展這個故事。這些接觸點共同營造出連貫且沉浸式的呈現，彰顯馬球衫作為真正標誌性單品的特質——它植根於運動，卻也與日常生活息息相關。此外，「源自賽場的經典」活動將配合美國兩項最重要的馬球賽事同步推出——包括享有盛譽的 USPA 金盃®（USPA Gold Cup®），以及全球競爭最激烈的賽事之一「美國公開馬球錦標賽®」（U.S. Open Polo Championship®），該賽事將於 4 月 26 日舉行冠軍決賽。「『源自賽場的經典』旨在擁抱我們的真實本質，並在國際舞台上大膽傳遞這份精神，」全球品牌行銷副總裁史蒂芬妮·科羅亞萊斯（Stefanie Coroalles）表示。「這場全球馬球衫宣傳活動融合了品牌傳承、產品特色與自我表達，展現了馬球衫如何從運動場域無縫融入日常生活。」「此次發布對我們而言是值得驕傲的時刻，它以現代、鮮明且無可辯駁的 U.S. Polo Assn. 風格，將我們的傳承賦予新生，」科羅亞萊斯補充道。產品核心理念：隨心所欲，盡情展現「每一件 U.S. Polo Assn. 馬球衫皆經過精心設計，在風格、舒適度、功能性與純正運動細節之間取得完美平衡，」品牌與產品開發資深副總裁布萊恩·卡米納（Brian Kaminer）表示。「從汲取傳統靈感的剪裁到現代機能面料，我們的 U.S. Polo Assn. 系列展現了馬球衫如何在忠於運動本源的同時，持續演進。」這場全球馬球衫宣傳活動透過五種獨特風格，展現這款經典單品的百變魅力，讓消費者在搭配馬球衫時，能盡情「隨心所欲，盡情展現」。「運動風」系列（Play It Sporty）的每一針每一線都承載著 U.S. Polo Assn. 的傳承。憑藉純正的細節、標誌性的品牌標識以及受運動啟發的元素，這款永恆的剪裁直接連結了品牌起源的馬球運動。官方徽章、經典剪裁與傳統設計細節，共同致敬馬球運動的歷史與品牌深厚的傳承。「Play It Classic」系列專為日常生活的點滴時刻而生。簡約、舒適且易於搭配，是您尋求百搭之選時的首選。這款專為反覆穿著而設計的 polo 衫，無論是休閒、放鬆或稍作打扮的場合，都能完美融入您的日常。「Play It in Motion」系列，專為動態活動打造的高性能POLO衫。採用先進技術面料，具備吸濕排汗的舒適感、透氣性及彈性，全天候隨您的動作靈活伸展。無論是球場上的POLO球員，還是追求動態生活的您，這款設計皆能兼顧耐用性與功能性，同時展現俐落現代的風格。「Play It Bold」系列，是專為自我表達而生的時尚POLO衫。這款作品以自信與風格為核心，為這款經典單品注入個性與自由。無論是隨性穿著或精心搭配，它都展現了當Polo衫由自信塑造、並依個人風格穿出時，其多變的魅力。「Play It Elevated」是為講究精緻的時刻打造的頂級Polo衫。採用高級面料與細膩工藝，呈現出精緻外觀卻不顯拘謹。簡潔的線條與貼合的剪裁，營造出沉穩而自信的風格，完美平衡了舒適與優雅。U.S. Polo Assn. 的季節性馬球衫涵蓋男裝、女裝及童裝系列，提供豐富多樣的面料、質感與色彩選擇——從經典中性色到鮮豔色調一應俱全。全新設計採用立體羅紋、低調圖案及精緻的工藝細節，並飾以品牌標誌性的「雙騎士」標誌——這不僅是正品的保證，更是這項運動的象徵。U.S. Polo Assn. 持續推出符合其全球永續發展計畫「USPA Life」的產品，體現品牌對負責任採購及長期環保倡議的承諾。將於 2027 年春季上市的 USPA Life 馬球衫，以 U.S. Polo Assn. 最具標誌性的款式為基礎，採用經過深思熟慮挑選的優質面料，彰顯品牌致力於改善這款經典單品對全球環境影響的決心。從 100% 優質棉面料到鈕扣與縫線等細節處理，每個環節皆經過精心挑選，在降低環境影響的同時，仍完整保留顧客對 U.S. Polo Assn. 馬球衫所期待的經典外觀、舒適度與品質。U.S. Polo Assn. 的服飾與配件現已於 U.S. Polo Assn. 實體門市及官網 uspoloassnglobal.com 販售。關於 U.S. Polo Assn. 與 USPA GlobalU.S. Polo Assn. 是美國馬球協會（USPA）的官方運動品牌。USPA 成立於 1890 年，是美國規模最大的馬球俱樂部與馬球選手組織。憑藉數十億美元的全球業務規模，以及透過超過 1,200 家 U.S. Polo Assn. 零售店和數千個其他銷售據點的全球分銷網絡，U.S. Polo Assn. 在全球 190 多個國家為男女及兒童提供服飾、配件和鞋類產品。該品牌贊助全球各大馬球賽事，包括每年於棕櫚灘的 NPC 舉辦的「美國公開馬球錦標賽®」（U.S. Open Polo Championship®），此為美國首屈一指的馬球錦標賽。透過與美國 ESPN、歐洲 TNT 和 Eurosport 以及印度 Star Sports 簽訂的歷史性合作協議，由 U.S. Polo Assn. 贊助的多項世界頂級馬球錦標賽現已透過電視轉播，讓全球數百萬體育迷首次得以欣賞這項令人熱血沸騰的運動。根據《License Global》的報導，U.S. Polo Assn. 一直與 NFL、PGA 巡迴賽及一級方程式賽車並列為全球頂尖的運動授權商之一。此外，這個以運動為靈感的品牌更因全球業務成長及運動內容而獲得國際獎項肯定。憑藉其作為全球品牌的巨大成功，U.S. Polo Assn. 曾獲《富比世》、《財星》、《現代零售》及《GQ》等媒體報導，並登上雅虎財經與彭博社等全球眾多知名媒體平台。欲了解更多資訊，請造訪 uspoloassnglobal.com 並追蹤 @uspoloassn。USPA Global 是美國馬球協會（USPA）的子公司，負責管理市值數十億美元的運動品牌 U.S. Polo Assn.。USPA Global 同時管理其子公司 Global Polo，該公司是全球馬球運動內容的領導者。欲了解更多資訊，請造訪 globalpolo.com 或 YouTube 上的 Global Polo 頻道。如需更多資訊，請聯絡：Stacey Kovalsky - 全球公關與傳播副總裁電話 +954.673.1331 - 電子郵件：skovalsky@uspagl.com  凱拉·德雷克（Kaela Drake） - 資深公關與傳播專員電話 +561.530.5300 - 電子郵件：kdrake@uspagl.com 消息來源：U.S. Polo Assn. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 聚焦於腫瘤治療領域的創新型生物製藥公司──樂普生物科技股份有限公司(「樂普生物」或「公司」，股份代號：2157.HK)公佈2025年全年業績。報告期內，公司業務及收入現強勁增長，首年實現盈利，全球首創EGFR靶向ADC美佑恆®獲批上市，核心產品商業化提速，多項國際授權合作順利推進。於報告期內，樂普生物收入實現顯著增加，總收入約為人民幣934.9百萬元，約為2024年收入的2.5倍。其中在國內商業化方面，普佑恆®（普特利單抗注射液）及美佑恒®（注射用維貝柯妥塔單抗）的收入約人民幣501.0百萬元，同比大幅增加66.8%；在許可業務方面，實現收入約人民幣424.2 百萬元，主要來自MRG007及TCE資產的對外授權。同時，公司首年實現盈利約人民幣261.4百萬元，較2024年大幅增加。經營現金流量持續向好，現金及現金等價物約為人民幣8.53億元，為2024年的兩倍以上。研發開支約人民幣4億元，較2024年同期下降8.5%，在保障核心管線推進的同時，成本控制成效顯現。核心產品商業化提速 兩項國際授權合作順利落地作為一家立足中國、面向全球的聚焦於腫瘤治療領域（尤其是靶向治療及免疫治療）的創新型生物製藥企業，樂普生物致力於通過全面且先進的ADC技術開發平台開發創新型ADC，並旨在開發出優化、創新的藥物，更好地填補癌症患者的臨床需求缺口。公司致力於通過充分整合自主創新能力及戰略合作，持續開發市場差異化產品管線。隨着ADC候選藥物進入商業化階段，公司已建立並正在逐步擴大內部生產能力以滿足業務發展的需求。目前，樂普生物已戰略性佈局了多個腫瘤產品管線。截至公告日期，公司擁有(i)兩種臨床/商業化階段候選藥物；(ii)八種臨床階段候選藥物，包括一種透過合營企業共同開發的藥物；及(iii)五種候選藥物的臨床階段聯合療法。公司有兩種候選藥物已就其靶向適應症獲得上市批准，其他適應症的臨床試驗正在進行中。在八種臨床階段候選藥物中，六種為靶向療法藥物，兩種為免疫治療藥物（分別為一種溶瘤病毒藥物及T細胞激動性抗體）。截至報告期末，通過國內商業化及業務開發活動，樂普生物在研發能力變現方面取得重要里程碑。普佑恆®（普特利單抗注射液）已完成商業化全流程，目前正處於銷售快速增長階段。憑藉這一勢頭，公司旨在優化美佑恆®（注射用維貝柯妥塔單抗）(FIC EGFR-ADC)的商業化策略，以推動更有效的市場滲透及增長。此外，另有兩款產品CMG901及MRG007也通過業務開發活動成功達成授權合作。CMG901的全球權益已授權予AstraZeneca，MRG007的大中華區以外地區權益已授權予ArriVent。多管線产品進入關鍵階段 創新ADC潛力釋放於2025年，樂普生物的全球首創EGFR靶向ADC美佑恆®已在中國獲得上市批准。同時，我們有更多候選藥物進入關鍵臨床階段，且通過開發及優化聯合治療方案實現了治療線數前移。CMG901(CLDN 18.2-ADC)：AstraZeneca於2023年2平台月獲授CMG901 (AZD0901)的研究、開發、註冊、生產及商業化獨家全球許可。AstraZeneca正積極進行CMG901的兩項III期臨床試驗：一項作為晚期/ 轉移性胃或胃食管連接部腺癌的單一療法，另一項作為與卡培他濱（伴有或不伴有rilvegostomig）聯合治療CLDN 18.2陽性和HER2陰性晚期/轉移性胃、胃食管連接部或食管腺癌的一線治療。根據許可協議，聯合試驗中首名患者的給藥已觸發45百萬美元的里程碑付款，該付款由AstraZeneca支付。MRG004A (TF-ADC)：目前正在中國進行治療PDAC的III期臨床試驗。於2025年8月，MRG004A獲國家藥監局CDE授予BTD。PC的Ib期擴展階段良好數據已於2025年ESMO大會上呈現。CG0070（溶瘤病毒）：目前公司的美國合作夥伴CG Oncology正進行CG0070的MRCT III期臨床研究。觀察到的最新良好數據已於第26屆SUO年會上作為LBA以口頭匯報形式呈現。截至2025年12月31日，公司已啟動國內關鍵臨床試驗的患者入組。此外，CG0070於2025年獲國家藥監局CDE授予BTD。MRG001 (CD20-ADC)：公司正在進行一項II期臨床研究，以評估MRG001聯合BTK抑制劑治療DLBCL患者的療效，該研究的良好中期數據已於第67屆ASH年會上呈現。MRG006A (GPC3-ADC)：MRG006A是一款基於新型拓撲異構酶I抑制劑且具有全球FIC潛力的GPC-3靶向ADC候選產品，乃基於Hi-TOPi ADC平台開發。目前正在中國進行HCC的II期臨床試驗。此外，公司獲得FDA的MRG006A IND核准，且該藥物獲FDA授予FTD及ODD認定。I期臨床研究的良好數據已讀出，並計劃於2026年ASCO大會上呈現。MRG007 (CDH17-ADC)：公司與ArriVent正於中國及美國同步進行一項針對不可切除的局部晚期或轉移性實體瘤治療的I期MRCT。於2025年AACR年會上呈現的MRG007的臨床前數據顯示出治療消化道癌的良好臨床潛力。於2025 年1 月，公司與Ar riVent訂立獨家許可協議，據此，公司授予ArriVent在大中華區以外地區開發、製造及商業化MRG007的獨家權利。根據協議條款，公司有資格獲得總計最高達12億美元的首付款及開發、監管及銷售里程碑付款，連同銷售淨額的分級特許權使用費。聯合療法布局：截至2025年12月31日，公司正在進行HNSCC的隨機、開放、多中心III期臨床研究。在美佑恆®與普特利單抗聯合治療方面，公司目前正在進行HNSCC的II期臨床試驗（該試驗已提線至一線治療），其II期臨床試驗的良好數據已於2025年ESMO大會上呈現。公司亦正在歐洲進行針對LA-HNSCC的II期臨床試驗。此外，公司獲得國家藥監局CDE關於在中國開展美佑恆®與普特利單抗聯合療法的IND批准，旨在評估該方案在手術干預前對術前LA-HNSCC患者的療效及安全性。創新平台：公司不斷努力建立和開發新的技術平台，作為公司的創新引擎，同時推動新型創新分子管線的持續進展。公司的研發平台—Hi-TOPi ADC平台及T細胞銜接器平台已成熟並經過驗證。除管線中的在研產品外，公司亦正通過自有研發平台積極開發多特異性抗體IO及多特異性抗體ADC候選藥物。公司計劃於2026年4月的AACR年會上呈現一款雙特異性ADC候選藥物及一款新型免疫腫瘤融合蛋白候選產品的臨床前數據。未來展望：加快後期產品的商業化 加大全球市場拓展力度在藥物研發方面，公司將進一步聚焦於推動下一代ADC藥物及免疫腫瘤雙╱ 三特異性抗體的戰略研發，同時加快後期產品的商業化。此外，公司的核心候選藥物正進入關鍵臨床階段。MRG004A目前正在進行III期臨床試驗的患者入組。CG0070已啟動國內關鍵臨床試驗的患者入組。公司亦將加快推進包括MRG006A及MRG007在內的其他創新候選藥物進入關鍵臨床階段。同時，我們正在不斷探索管線內聯合療法的潛在療效，努力為更廣泛的患者群體帶來更大的臨床效益。在國內商業化方面，公司將繼續集中資源及努力推動商業化進程，專注於提高獲批產品的市場佔有率及銷售表現。公司將採取進一步措施提高這兩款產品的市場可及性，加快各級市場滲透，進一步擴大市場份額。憑藉商業化團隊的專業知識及行業資源，公司將尋求通過市場營銷、學術推廣等各種方式提升品牌形象及市場認知度。同時，公司將根據美佑恆®（注射用維貝柯妥塔單抗）的實際銷售表現優化商業化策略，並利用已全面擴大的營銷及商業化團隊，專注於推動總收入增長。在國際方面，公司將加大在全球市場的拓展力度，堅持不懈地擴大國際網絡，並探索新的業務開發合作機會。公司將繼續致力於在全球範圍內尋找更多戰略合作夥伴，通過合作、授權協議或合營企業等方式開發ADC產品和其他創新候選藥物。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - March 26, 2026) - Casa Minerals Inc. (TSXV: CASA) (OTCQB: CASXF) (FSE: 0CM) (the "Company" or "Casa") is pleased to announce that it has received a large dataset of historic drill hole information from the Congress Gold Mine Project in Yavapai County, Arizona, USA. Comprehensive desktop technical studies integrating this data with the Company's own 2022 drilling campaign have resulted in the identification and delineation of three distinct priority exploration zones that will form the basis of the 2026 field and drilling program.HIGHLIGHTSReceipt of a large historic drill hole database greatly expanding the geological model for the Congress Gold Mine Project3D modelling of over 100 historic and recent drill holes confirms strong structural integrity and continuity of the gold-bearing vein systemsThree distinct exploration zones classified: Echo Bay Exploration Zone (~750m x 1,000m), Malartic Exploration Zone (~450m x 1,150m), and New Congress Niagara Exploration Zone (~800m x 1,000m)Echo Bay Exploration Zone designated highest priority target based on historic drill density and potential for expanded mineralization envelopeHistoric drill intercepts include highlights such as 1.2m @ 43.88 g/t Au, 2.0m @ 21.88 g/t Au, 3.3m @ 27.13 g/t Au, and 11.4m @ 4.81 g/t Au within the Echo Bay ZoneCongress Gold Mine Project is fully permitted with excellent road access and proximity to an experienced regional labor forceCompany geologists and field personnel are being mobilized for initial site preparation and drill program setupHISTORIC DRILL DATABASE COMPILATIONCasa Minerals is pleased to announce the receipt of a comprehensive dataset of historic drill hole collars, surveys, and assay records from the Congress Gold Mine Project. This data was compiled from exploration programs conducted by previous operators -- most notably Echo Bay Mines Ltd. -- during the 1980s through the early 1990s. The database encompasses a significant number of drill holes distributed across the project area, substantially expanding the known geological framework of the property.Historic exploration at the Congress Gold Mine was conducted during a period when gold market conditions were materially lower than today's environment, which directly influenced the selection criteria and cut-off grades used by previous operators. Consequently, the historic programs focused predominantly on higher-grade gold intersections, and many lower-grade vein intercepts that may be economically significant at current gold prices were not assigned the same level of analytical priority. Casa believes this creates a meaningful opportunity to reinterpret the mineralization system with a lower economic threshold, logically expanding the dimensions of the mineralization envelope that will be targeted in the forthcoming drilling season.Important Disclosure: The historic drill hole results referenced in this news release were collected and reported by previous operators under practices that predate current NI 43-101 standards. These results are disclosed solely for contextual and geological interpretation purposes. They have not been verified by a current Qualified Person, do not conform to NI 43-101, and are not classified as current mineral resources or mineral reserves. A Qualified Person has not done sufficient work to classify the historic results as current mineral resources or mineral reserves, and Casa is not treating them as such.THREE-DIMENSIONAL MODELLING AND VEIN SYSTEM VALIDATIONDesktop technical studies have included rigorous 3D modelling of all available drill hole data using industry-standard geological modelling software. The resulting three-dimensional representation of the drill hole database, illustrated in Figure A below, demonstrates the remarkable density of historic drill coverage across the project and confirms the structural coherence and continuity of the principal gold-bearing vein systems.The 3D model was constructed using NAD83 / UTM Zone 12N coordinates and captures drill holes ranging from surface to depths approaching 600 metres below ground elevation. The model reveals that:The dominant vein systems exhibit strong northeast-southwest structural orientation, consistent with the principal fault architecture identified on surfaceThe alignment and attitude of vein structures intercepted in the Company's 2022 confirmatory drilling campaign correlate with high fidelity to those projected from the historic drill hole database, validating the overall geological modelThe 2022 drilling campaign identified additional vein structures not captured in the historic database, indicating that the current geological model is likely incomplete and that the total mineralized footprint may be materially larger than previously understoodIncorporating lower-grade vein intercepts -- previously deprioritized by historic operators under lower gold price conditions -- into the mineralization envelope substantially increases the aggregate target volume for future drillingFigure A: Four-panel 3D presentation of historic and recent drill hole collars and traces, Congress Gold Mine Project. Views from west (upper left), east (upper right), oblique (lower left), and plan (lower right). Coordinate system: NAD83 / UTM Zone 12N. The high density of drill traces illustrates the extensive historic exploration coverage across the project area. Pink/magenta traces represent historic drill holes; black traces represent more recent drilling. Purple lines denote projected vein orientations.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_001full.jpgTHREE PRIORITY EXPLORATION ZONES -- 2026 PROGRAM BASISDetailed integration of the historic drill database with geological mapping, vein system mapping conducted in 2022, and structural interpretation has enabled Casa to formally classify three distinct priority exploration zones within the Congress Gold Mine Project. The classification of each zone reflects the combination of historic drill density, vein system geometry, and the nature of the gold mineralization documented to date. Figures 1 through 4 present these zones in their regional and local contexts.Figure 1: Regional overview map of the Congress Gold Mine Project showing principal vein systems (red dashed), fault corridors (blue dashed), shaft locations (Shafts 1 through 6), historic stope outlines (yellow, 1959-1987), patented claim and BLM claim outlines, and the location of the three principal exploration zones. The project is situated in Yavapai County, Arizona.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_002full.jpgEcho Bay Exploration Zone -- Highest Priority TargetThe Echo Bay Exploration Zone, measuring approximately 750 metres by 1,000 metres, is the largest and most intensively drilled zone on the property. It encompasses the historic non-NI 43-101 resource outline that was previously defined by Echo Bay Mines and represents the core of the historic gold-producing system at Congress. The zone is bounded by the principal northeast-trending veining corridors and is cut by northwest-trending fault structures that locally displace but do not terminate the mineralized vein arrays.As illustrated in Figure 2, the Echo Bay Exploration Zone hosts a dense cluster of historic drill hole intercepts distributed across the full extent of the zone. The drill hole collars and assay intercepts depicted in the figure provide compelling evidence for broad, zone-scale gold mineralization. Notably, the higher-grade intercepts are concentrated along the principal vein corridors while lower-grade disseminated and stockwork gold is documented in the intervening ground. This spatial distribution is characteristic of orogenic gold systems and is consistent with the geological setting at Congress.Selected historic drill intercepts within the Echo Bay Exploration Zone include:1.2m @ 43.88 g/t Au -- exceptional high-grade intercept within the principal vein corridor3.3m @ 27.13 g/t Au -- high-grade intercept demonstrating vein width and continuity2.0m @ 21.88 g/t Au -- high-grade vein intercept in the central portion of the zone2.4m @ 19.03 g/t Au -- confirming strong grade continuity along strike11.4m @ 4.81 g/t Au -- broad, elevated-grade intercept indicative of wide mineralization envelopes within the vein system1.5m @ 15.28 g/t Au -- demonstrating high-grade vein core and broader lower-grade haloes2.0m @ 12.19 g/t Au and 7.3m @ 11.00 g/t Au -- further confirming grade and continuity of the principal vein arrays3.1m @ 11.19 g/t Au and 2.0m @ 15.63 g/t Au -- documented in the southwestern portion of the zone, indicating lateral continuityGiven the historic drill density, the documented grade profile, and the alignment of the 2022 confirmatory drilling with the historic vein model, the Echo Bay Exploration Zone has been assigned the highest exploration priority for the 2026 program. The Company views the zone as offering the clearest near-term pathway to NI 43-101 resource delineation.Figure 2: Detailed plan map of the Echo Bay Exploration Zone (~750m x 1,000m), Congress Gold Mine Project. Shown are historic drill hole intercepts (brown dots annotated with interval length in metres and gold grade in g/t), principal vein system traces (red dashed), fault corridors (blue dashed), historic stope outlines (yellow), shaft locations, and the historic non-NI 43-101 resource outline (red hatch). Selected intercepts include 1.2m @ 43.88 g/t Au, 3.3m @ 27.13 g/t Au, 11.4m @ 4.81 g/t Au, and 2.4m @ 19.03 g/t Au, among numerous others. To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_003full.jpgMalartic Exploration ZoneThe Malartic Exploration Zone covers an area of approximately 450 metres by 1,150 metres and is situated to the south and southeast of the Echo Bay Exploration Zone. The zone is named after the "Malartic-style" stratabound and vein-hosted gold mineralization that has been documented in this area of the project. Historic shaft locations CGC-003 and CGC-004 are located within this zone, providing direct underground access for potential future development.The Malartic Exploration Zone is characterized by multiple subparallel northwest-striking vein sets that have been intercepted in a series of shallow to moderate-depth drill holes. The vein system includes documented vein widths of 27 feet, 38 feet, and 55 feet (as labelled on Figure 3), indicating substantial structural corridors capable of hosting economically significant gold mineralization.Representative historic drill intercepts within the Malartic Exploration Zone include:3.6m @ 0.74 g/t Au and 10.3m @ 1.73 g/t Au -- broad lower-grade intercepts within the principal vein corridor demonstrating wide mineralization envelopes10.36m @ 1.41 g/t Au and 8.1m @ 3.53 g/t Au -- moderate-grade intercepts confirming continuity of the vein arrays7.7 @ 3.56 g/t Au and 8.1m @ 2.53 g/t Au -- further demonstrating consistent grade within vein-hosted mineralization3.2m @ 7.72 g/t Au and 2.8m @ 9.41 g/t Au -- higher-grade intercepts at the northern margin of the zone (shared boundary with the Echo Bay Zone)The Malartic Exploration Zone is relatively underexplored compared to the Echo Bay Zone, and the relatively sparse drill coverage suggests significant upside potential for zone expansion with systematic drilling.Figure 3: Detailed plan map of the Malartic Exploration Zone (~450m x 1,150m), Congress Gold Mine Project. Shown are historic drill hole intercepts (annotated with gold values), principal vein system traces, shaft locations including CGC-003 and CGC-004, historic stope outlines, and documented vein widths of 8.2m, 11.6m, and 16.8m.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_004full.jpgNew Congress Niagara Exploration ZoneThe New Congress Niagara Exploration Zone, measuring approximately 800 metres by 1,000 metres, is the northernmost of the three classified exploration zones and is situated along a structurally distinct corridor characterized by the northwest-striking New Congress-Niagara fault system. This zone encompasses historic Shaft 1 as well as drill holes CGC-008, CGC-009, and CGC-010 from the Company's 2022 exploration program.The 2022 drilling in this zone identified four discrete veins with widths ranging from 49.5 feet to 206 feet -- a notably wide structural corridor. These widths are illustrated in Figure 4 as Vein 49.5 ft, Vein 55 ft, Vein 70.5 ft, and Vein 206 ft. The scale of these structural features highlights the potential for significant bulk-tonnage style mineralization within this zone, distinct from the higher-grade but narrower veins documented in the Echo Bay Zone.Critically, the 2022 drilling at the New Congress Niagara Zone identified several vein structures that are not represented in the historic drill database, reinforcing the Company's view that the existing geological model incompletely captures the full scope of the vein system. This structural incompleteness, combined with the relatively limited historic drill coverage of this zone, underscores its exploration potential.Figure 4: Detailed plan map of the New Congress Niagara Exploration Zone (~800m x 1,000m), Congress Gold Mine Project. Shown are drill hole locations from the 2022 exploration program (CGC-008, CGC-009, CGC-010) alongside Shaft 1, with identified vein widths of 49.5 ft, 55 ft, 70.5 ft, and 206 ft. The purple outline denotes the exploration zone boundary.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_005full.jpgPROJECT STATUS AND 2026 FIELD PROGRAMThe Congress Gold Mine Project is fully permitted for exploration and mining activities in Yavapai County, Arizona. The property benefits from:Fully permitted status: All necessary exploration and access permits are in place, enabling rapid mobilization of field crews and drilling equipmentExcellent road access: Paved and maintained road access to the property boundary facilitates cost-effective equipment and supply logisticsExperienced regional labor force: The Yavapai County region has a well-established mining and exploration workforce with proven experience in gold exploration projects of this typeInfrastructure: Existing shaft infrastructure and historic workings provide geological reference points and potential future development opportunitiesThe Company is currently mobilizing a team of geologists and field personnel to the Congress Gold Mine Project for initial site preparation, geological review, and establishment of the field infrastructure required for the 2026 drilling program. Detailed drill program parameters, including planned hole locations, depths, and targeting rationale, will be provided in a subsequent technical news release.MANAGEMENT COMMENTARY"The receipt of this historic drill database is a genuinely significant development for Casa Minerals," stated Farshad Shirvani, President and CEO. "For the first time, we now have a comprehensive view of the full scope of historic exploration at Congress, and what we see is highly encouraging. The 3D model clearly validates our 2022 findings and demonstrates that the gold system is both continuous and larger than historic estimates suggested. With gold trading at current levels, the lower-grade vein intercepts that were historically deprioritized now become compelling exploration targets in their own right. The Echo Bay Zone, with intercepts like 1.2m @ 43.88 g/t and 11.4m @ 4.81 g/t, gives us a very strong foundation from which to build a modern NI 43-101 resource. We are mobilizing our team and look forward to reporting our first drill results from the 2026 season."QUALIFIED PERSONMr. Erik Ostensoe, P.Geo., a Director and Chief Geologist of the Company, a Qualified Person as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects, has reviewed and approved the scientific and technical disclosure in this news release.ABOUT CASA MINERALS INC.Casa Minerals Inc. is a mineral exploration company focused on gold, copper, and strategic minerals exploration in North America. The Company holds a 90% interest in the historic Congress Gold Mine in Arizona and is advancing multiple projects in British Columbia, including the Arsenault copper-gold-silver project. Casa's experienced management team is committed to creating shareholder value through the discovery and development of economic mineral deposits. For more information, please visit: www.casaminerals.comON BEHALF OF THE BOARD OF DIRECTORSFarshad Shirvani, M.Sc. GeologyPresident, CEO and DirectorFor more information, please contact:Casa Minerals Inc.Farshad Shirvani, President & CEOPhone: (604) 678-9587Email: contact@casaminerals.comCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding: the Company's exploration plans and programs for 2026; anticipated drilling activities at the Congress Gold Mine Project; the classification and prioritization of exploration zones; expectations regarding resource definition and the potential to advance the project to NI 43-101 compliant standards; interpretations of historic drill data and 3D geological models; mineralization potential and domain expansion; and mobilization of field personnel. Forward-looking information is based on the opinions and estimates of management at the date the information is made and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated. Such factors include, without limitation: uncertainties regarding exploration results; risks related to the accuracy and completeness of historic data; the inability to verify historic assay results; variations in mineralization and grade; the speculative nature of mineral exploration; challenges in obtaining required permits and approvals; fluctuations in commodity prices; availability of financing; changes in economic and market conditions; environmental and regulatory risks; operating hazards; and other risks inherent in the mineral exploration industry. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290037 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) – March 19, AAC Technologies Holdings Inc. (HKEX Stock Code: 2018) held its 2025 Annual Results Announcement Conference in Singapore and reported a strong set of annual results. The Group achieved RMB 31.82 billion in annual revenue, representing a 16.4% year-on-year increase and marking a record high of over RMB 30 billion, with net profit rising 39.8% to RMB 2.51 billion. These results reflect the continued success of the Company’s strategic transformation, with revenue reaching new highs in recent years and net profit delivering sustained double-digit growth.“Pioneering Innovation” and “AI Empowerment” have emerged as the central themes of AAC’s recent developments, driving its strategic transformation from a traditional component supplier to a builder of AI perception infrastructure.In an interview during the conference, AAC’s Chief Financial Officer, Guo Dan, highlighted that the Company’s strategic new business lines — represented by optics and automotive solutions — together with its expansion into high-potential AI sectors such as heat dissipation, robotics, and XR, have become the key growth engines supporting mid-to-long-term sustainable development. This strong momentum is expected to continue unlocking further growth potential in 2026.Looking ahead to 2026, Dan expressed strong confidence. Despite persistent industry volatility, the Group will capitalize on its diversified business portfolio to deliver steady revenue growth, with the growth rate expected to be no lower than that of 2025. At the same time, the gross profit margin is projected to improve steadily from the 22.1% baseline in 2025.( AAC Technologies CFO Guo Dan)1. On the Optics Business: Plastic Lens Gross Margin to Rise to 35%, with Proprietary WLG Technology Reaching Key MilestoneAs a core strategic growth driver, AAC’s optics business (AAC Optics) has achieved rapid development since in 2019. It reported RMB 5.73 billion in revenue in 2025, with a compound annual growth rate (CAGR) exceeding 32% over the past six years, establishing itself as a key pillar of the Group’s overall growth.Dan stated that in 2026, the optics business is expected to deliver steady revenue growth while further improving its gross margin. In 2025, the Company continued to upgrade its mid-to-high-end lens product mix, with the shipments of lens products with 6 or more elements accounting for over 18% of the total and seven-element (7P) lens shipments reaching 15 million units. Building on this foundation, the gross profit margin of plastic lenses is projected to rise from 30% in 2025 to 35% in 2026, reaching a industry-leading level.Notably, AAC has made a significant breakthrough in its globally proprietary Wafer-Level Glass (WLG) lens technology, reaching a key milestone. This advancement not only expands the scope of application scenarios but is also expected to drive a shift in the market landscape traditionally dominated by plastic lenses. Dan added, “In the future, whether in smartphones, automotive solutions, or emerging smart terminal devices, we will see more stable incremental growth that will inject long-term momentum into our business growth.”2. On the Automotive Solution Business: The "Second Growth Engine" Solidifies, with 2026 Revenue Expected to Grow by 15%-20%Through the acquisition of Premium Sound Solutions (PSS), AAC has rapidly established a core platform in the smart automotive solution sector, successfully developing a second growth engine for the Company.Dan revealed that following the acquisition of PSS in 2024 and the acquisitions of Chuguang and PSG in 2025, the Company has become a comprehensive system-level automotive solution provider, expanding its business from smartphones into the entire automotive domain. In 2025, the Company’s automotive acoustics business recorded revenue of RMB 4.12 billion, representing a year-on-year increase of 16.1%. This performance has positioned AAC among the world’s top-tier automotive audio system suppliers, second only to industry leaders such as Harman and Bose.Regarding the 2026 outlook for the automotive acoustics business, Dan stated that the segment is expected to maintain high double-digit growth of 15% to 20%, while keeping the gross margin stable. The Company’s automotive solution business has now achieved broad customer coverage both in China and overseas, including multiple Asian markets. This diversified regional presence is expected to provide steady and reliable support for both revenue and profit growth.3. On AI Sectors: Heat Dissipation Business Poised to Reach RMB 10 Billion, with Explorations in XR and Robotics Opening New FrontiersIf optics and automotive solutions represent the Company’s “core growth engines,” then business lines such as heat dissipation, robotics, and XR optical waveguides constitute the high-potential “reserves” for AAC’s future development. Dan noted that the Company’s revenue in the past was primarily driven by traditional mobile phone acoustics and haptics business. However, following years of strategic transformation and amid broader industry technological shifts, AI has become the fundamental driver underpinning the sustained growth of the Company’s multiple product lines.“For example, the rapid growth of the heat dissipation business is mainly attributable to AI-driven demand. Similarly, our initiatives in robotics and AR glasses are also propelled by AI,” Dan explained. In 2025, the Company’s heat dissipation business recorded revenue of RMB 1.67 billion, grew by 410.9% year-on-year. This performance has further solidified the Company’s position as one of the leading global suppliers in consumer electronics heat dissipation. “As AI technology continues to advance, related application scenarios are expected to extend from smartphones to a wider range of devices, including laptops and tablets, generating strong momentum for the Company’s overall growth.”The acquisition of Yuandi Technology, with more notable strategic significance, has allowed AAC to formally enter the data center liquid cooling, AI server heat dissipation, and high-end thermal solutions sectors, and extend its capabilities from “terminal-side heat dissipation” to “AI infrastructure heat dissipation” creating a synergistic “terminal + infrastructure” development model. Dan stated clearly, “Leveraging the substantial market opportunities across multiple sectors, our heat dissipation business has the potential to reach and even exceed a scale of RMB 10 billion in the coming years, positioning it as a highly promising and important growth engine for the Group.”In the XR optical waveguide field, through the acquisition of Dispelix — a global leader in AR diffractive waveguide technology — AAC has become one of the few industry players with vertically integrated capabilities spanning optical waveguide design and manufacturing. The Company can now offer one-stop full display module solutions, encompassing optical waveguides, optical engines, push-pull lenses, eye-tracking systems, and electrochromic technology. AAC is expected to become the world’s first supplier to achieve mass production of SRG full-color optical waveguides for leading customers in 2026. Dan disclosed, “The per-unit value in the optics business can reach USD 100–200. These initiatives are expected to deliver clear mass production and shipment opportunities within the next two to three years, continuously generating significant value in revenue, profit, and long-term market expansion.”Regarding the robotics field, Dan pointed out that the industry’s market definition, application scenarios, and product forms are still evolving and remain in a diverse exploratory stage. AAC has long maintained deep involvement and has established comprehensive layouts across multiple core areas, including acoustics, motors, optics, structural components, and electromechanics, laying a solid foundation to capture opportunities as the sector matures. “For example, our dexterous hand products for humanoid robots have already entered mass production and shipments, generating over RMB 100 million in revenue last year. In addition, we are co-developing the first motor, as a core component for AI hardware devices, with our customers. Overall, the Company has built deep cooperation with leading domestic and international customers, and we believe we will become an important player in this field in the future.”4. Strategic Review: Combining Technology Reuse with Ecosystem Construction to Anchor Long-Term GrowthIn AAC’s three-decade development journey, the core driver behind its sustained growth has consistently been rooted in the dual logic of technology reuse and ecosystem construction.Leveraging its long-established, robust technological foundations in micro-acoustics, precision optics, electromagnetic drives, sensors, and semiconductors, the Company has successfully upgraded and expanded its business, with its focus shifting from mobile phones and consumer electronics to emerging high-growth areas, including AI terminals, robotics, XR, smart vehicles, and data center infrastructure. This approach enables its core technological capabilities to be efficiently migrated and continuously amplified across diverse application scenarios.This development model — “upgrading application scenarios without changing underlying technology” — not only ensures the stability and success rate of business transformation but also allows the Company to rapidly address capability gaps through strategic ecosystem integration, such as the acquisitions of Dongyang, PSS, Chuguang, and Yuandi. Together, these efforts have created a virtuous cycle of “technology–product–scenario–customer.”The clear pathway to realizing this cycle was articulated by Dan in her outlook: Looking ahead to 2026 and beyond, AAC will position itself as a “builder of AI perception infrastructure,” deepen cross-business synergy and full-scenario coverage, accelerate its expansion into the “AI blue ocean,” strengthen its global footprint, and continue riding the wave of industry development to achieve new heights.source as Forbes（https://www.forbeschina.com/investment/71292） Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 3月19日，瑞聲科技（2018.HK）在新加坡舉辦2025年度業績發布會，交出了亮眼的「年度答卷」。財報顯示，瑞聲科技2025年收入人民幣318.2億元，歷史首次突破300億元大關，同比增長16.4%。淨利潤達 25.1 億元，同比大幅增長39.8%。公司近年來營收規模屢創新高，淨利潤實現高雙位數增長，戰略轉型成效凸顯。 「向新而行」與「AI賦能」已成為瑞聲科技近年發展的核心關鍵詞，而這背後正是公司從元器件供應商向「AI感知基礎設施構建者」的深刻轉型。瑞聲科技CFO郭丹在業績發布會訪談中強調，以光學、車載為代表的戰略新業務，疊加散熱、機器人、XR 等AI藍海賽道布局，已構建起公司中長期可持續增長的核心動力引擎，2026年將持續釋放增長潛力。展望2026年，郭丹表示充滿信心。儘管行業仍存在波動，集團將依託多元業務引擎，實現全年穩健的收入增長，增速預計不低於2025年的水平。同時，毛利率也將在2025年22.1%的基礎上穩步提升。（受訪者：瑞聲科技CFO郭丹）01、談光學業務：塑膠鏡頭毛利率將升至35%，獨家WLG技術迎關鍵里程碑作為公司戰略核心增長點，瑞聲科技光學業務（辰瑞光學）自2019年確立布局以來實現跨越式發展。數據顯示，光學業務2025年營收已攀升至57.3億元，六年期間年均複合增長率（CAGR）超32%，成為集團增長的重要支柱。郭丹介紹，2026 年公司光學業務將實現穩健增長，毛利率亦同步提升。2025年，公司持續優化中高端鏡頭產品結構，6P及以上規格鏡頭出貨占比突破18%，7片式鏡頭出貨量達1500 萬顆。在此基礎上，2026年塑膠鏡頭毛利率將從2025 年的30% 提升至 35%，達到行業領先水平。值得關注的是，瑞聲科技全球獨家的WLG玻璃鏡片技術實現歷史性突破，迎來關鍵里程碑，不僅拓寬了應用場景邊界，還有望重構全球塑膠鏡頭主導的市場格局。郭丹表示，「未來無論是手機、車載領域，還是新興智能終端形態，都會看到更多更穩健的增量為業務增長注入長期動能。」02、談車載業務：「第二增長極」穩固，2026年營收預計增長15%-20%通過收購PSS 公司，瑞聲科技快速搭建起智能車載領域的核心平台，成功培育出助推公司發展的「第二增長極」。郭丹透露，公司2024年完成PSS 收購，2025年併購初光、PSG，已全面升級為車載領域系統級解決方案提供商，業務版圖從智能手機拓展至汽車全域。2025年公司車載聲學業務收入達41.2億元，同比增長16.1%，躋身僅次於Harman、Bose的全球頭部車載音頻系統供應商行列。針對車載聲學業務2026年發展前景，郭丹表示，業務有望保15%-20%的高位雙位數增長，毛利率將保持穩健。目前公司車載業務已實現海外、國內及亞洲多地客戶的全面拓展，多區域布局將為營收與利潤帶來穩健且確定的增長支撐。03、談AI藍海業務：散熱業務未來規模有望達百億，XR、機器人再拓新局如果說光學、車載是公司的「核心增長引擎」，那麼散熱、機器人、XR光波導等業務則是瑞聲科技布局未來的高潛「後備軍」。郭丹認為，公司過往營收主要依託以傳統手機聲學與觸覺等為代表的業務，而歷經數年戰略轉型，疊加行業技術變革，AI已成為驅動公司多產品線持續成長的核心基石。「比如，散熱業務增長為什麼會這麼快？主要還是來自於AI需求，包括機器人、AR眼鏡的布局也是來自於AI需求。」郭丹介紹，2025年公司散熱業務營收同比增長4倍至16.7億元，穩居消費電子散熱全球頭部供應商地位。「未來隨着AI持續發展，相關應用將從智能手機進一步延伸至筆電、平板等更多品類，實現更廣泛的場景覆蓋，為公司增長提供強勁動能。」而更具戰略意義的是，通過收購遠地科技，瑞聲科技正式進軍數據中心液冷、AI 服務器散熱及高端熱管理領域，實現從「終端散熱」向「AI基建散熱」的場景延伸，形成「終端+基建」雙賽道協同發力的格局。郭丹明確表示：「依託多業態帶來的廣闊市場機遇，我們的散熱業務有望在未來幾年間實現百億級規模，成為集團極具潛力的重要增長引擎。」在XR光波導領域，瑞聲科技通過收購全球領先的AR衍射光波導企業Dispelix，成為業內少數具備光波導設計與製造垂直整合能力的廠商，可提供光波導、光引擎、推/拉透鏡、眼動追蹤及電致變色等一站式全顯示模組解決方案，並預計於2026年成為全球首家向頭部客戶量產SRG全彩光波導的供應商。郭丹透露，「光學業務單機價值量可達100–200美金，相關布局未來兩三年內有望迎來明確量產出貨機遇，將從營收、利潤及長期市場增量等多方面持續創造顯著價值。」針對機器人領域，郭丹指出，當前行業的市場定義、應用場景及產品形態尚未完全定型，仍處於多樣化探索發展階段。而瑞聲科技長期深耕聲學、馬達、光學、結構件、電機等多個核心領域，並已完成深度布局，為把握行業成熟後的增長機遇築牢基礎。「比如，我們的人形機器人靈巧手相關產品已經批量出貨，去年收入規模就超過了1億元。另外，我們正在與客戶開發第一款AI硬件設備中的核心零部件電機。整體來看，公司已與國內外頭部客戶都建立深度合作，相信未來會是其中的一個重要玩家。」04、戰略復盤：技術復用+生態構建，錨定長期增長梳理瑞聲科技三十載發展脈絡，其持續增長的核心密碼，始終根植於技術底座復用 + 生態協同構建的雙重邏輯。依託在微型聲學、精密光學、電磁傳動、傳感器及半導體領域長期積澱的硬核技術底座，公司成功實現從手機等消費電子主賽道，向AI終端、機器人、XR、智能汽車、數據中心基建等新興領域的跨越升級，讓核心技術能力在多元場景中高效遷移、持續放大。這種「底層技術不變，應用場景迭代」的發展模式，既保障了業務轉型的穩定性與成功率，又通過生態整合（如收購東陽精密、PSS、初光、遠地科技）快速補全能力短板，形成「技術-產品-場景-客戶」的正向循環。而打通這一循環的關鍵路徑，已在郭丹的展望中清晰呈現：面向2026年及未來，瑞聲科技將錨定「AI感知基礎設施構建者」定位，深化多業務協同與全場景覆蓋，加速奔赴「AI藍海」，深耕全球化布局，推動公司乘勢而上、再攀高峰。source as Forbes（https://www.forbeschina.com/investment/71292） Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

 財務摘要截至2025年12月31日止年度(百萬港元)20252024變動收入 4,001.13,811.9+ 5.0%毛利 1,385.11,312.1+ 5.6%毛利率34.6%34.4%+ 0.2個百分點本公司擁有人應佔溢利 331.4201.0+ 64.9%純利率 8.3%5.3%+ 3.0個百分點經調整EBITDA 622.8612.5+ 1.7%每股盈利（港仙） 31.7619.26+ 64.9%香港, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 日清食品有限公司（「日清食品」或「公司」，連同其附屬公司統稱「集團」；股份代號：1475）今天公布截至2025年12月31日止年度之全年業績。 集團的收入由2024年的3,811.9百萬港元按年增加5.0%至2025年的4,001.1百萬港元，由於核心即食麵業務持續增長、中國內地消費情緒改善及海外市場需求增加所致。毛利由2024年的1,312.1百萬港元增加5.6%至2025年的1,385.1百萬港元；毛利率由2024年的34.4%微升0.2個百分點至2025年的34.6%。由於集團透過優化銷售組合及持續推行成本效益措施，有效紓緩成本壓力，支持毛利率提升。本公司擁有人應佔溢利大幅增加64.9%至331.4百萬港元，相當於年內純利率8.3%。溢利及盈利能力較去年大幅改善，乃由於營運效率提升以及上年度曾確認資產減值虧損之非現金費用。集團的每股基本盈利增至年內的31.76港仙，經調整EBITDA水平由2024年的612.5百萬港元增加1.7%至2025年的622.8百萬港元，相當於年內經調整EBITDA利潤率15.6%（2024年：16.1%）。董事會建議派發末期股息每股15.88港仙，派息率為50.0%。各業務地區之業務回顧及前景年內，來自香港及其他地區業務的收入增加7.7%至1,658.7百萬港元，主要由於香港即食麵業務表現穩健及其他地區需求增加；分部業績上升16.1%至152.8百萬港元，主要由於高端即食麵銷量持續增長。同時，中國內地業務於年內錄得收入2,342.4百萬港元，温和增長3.1%；分部業績增加3.5%至339.9百萬港元，主要由於集團持續致力拓展內陸地區銷量，以及中國內地業務的銷售勢頭持續。在香港，為持續豐富即食麵產品組合，公司推出多款新單品，包括合味道杯麵京都雞白湯味及咚兵衛肉汁味杯烏冬（即食麵）。為推動銷量及促進消費者互動，合味道及出前一丁與虛擬歌手「初音未來」合作。此外，公司亦透過指定微信小程式加強餐飲渠道的數碼化營銷。為配合針對冷凍食品業務的高端化策略，公司推出日清The Chef’s Signature系列，以滿足追求在家享受高質極致美食體驗之消費者需求。公司持續擴大非麵類產品組合，以時令產品加強其飲料產品線，以及推出全新一口裝日清迷你可可脆。此外，香港製造的日清穀物麥片及鮮切蔬菜持續獲得注重健康的消費者青睞，展現本公司對於健康、養生及營養的堅定承諾。在海外市場，集團在推行策略市場擴展及提升品牌方面取得重大進展。越南仍為東南亞快速增長的經濟體之一，公司透過拓展其銷售及分銷渠道至現代零售渠道，並以新產品鎖定年輕消費者群體把握強勁的消費者需求。台灣方面，公司在當地成立全資附屬公司，為合作夥伴提供更清晰的銷售方向及加強對他們的支援，促進銷售動力及長期業務增長。韓國方面，隨著韓流在全球的熱潮日益擴張，韓國業務取得穩健表現。集團亦憑藉其全球銷售網絡，將Gaemi Food Co. Ltd.（「Gaemi Food」）的零食產品推廣至新的海外市場。在澳洲，公司加強與ABC Pastry Holdings Pty Ltd（「ABC Pastry」）的營運整合，同時把握主流及亞洲零售渠道對亞洲美食日益增長的興趣，拓闊公司的即食麵產品銷售網絡。在中國內地，公司的表現穩健，主要由於即食麵銷量擴張，以及公司策略性擴展內陸地區的業務據點。為提升消費者參與度及品牌知名度，公司增加店內試食活動、加強微信小程式等平台的數碼化營銷，並與日本虛擬歌手「初音未來」高調合作，加強促銷活動。作為高端化策略的一部分，公司為豐富其產品組合，推出了日清咚兵衛油豆腐炸烏冬麵杯麵等新產品。非麵類業務亦錄得正面發展；分銷業務擴大了產品組合，新增歐洲瓶裝水、日本碳酸飲料以及日本巧克力及曲奇餅等高端進口產品，而零食業務則受惠於其薯片及節日產品，例如限量版可可脆粒等，取得良好表現。為展現對中長期發展的堅定承諾，集團以總代價人民幣30.68百萬元收購了兩塊珠海地塊的土地使用權。集團計劃投資超過人民幣240百萬元收購該等地塊，於該等地塊上建設新廠房及安裝新生產線。日清食品執行董事、董事長兼首席執行官安藤清隆先生表示：「我們對公司的增長前景保持謹慎樂觀的態度，同時持續專注於成本控制和運營效率。全球經濟復甦之路崎嶇不平，主要由於地緣政治局勢緊張及保護主義抬頭導致供應鏈重組。在此背景下，集團仍將致力於在需求明確且具可持續性的市場中，持續推動產品升級及強化執行能力。香港政府的相關舉措可望支撐經濟及家庭開支，為我們產品組合持續高端化提供更有利的環境。中國內地的中產階級不斷壯大為我們帶來巨大機遇，而越南蓬勃發展的零售業以及韓國對健康的關注亦將支持公司戰略發展。此外，澳洲對高品質冷凍食品的需求不斷上升，亦具有寶貴的增長潛力。我們透過高端化及多元化策略，增強在這些地區的競爭力。憑藉穩健的財務狀況、現金流生成能力及強大的品牌認受性，在中期至長期內我們將具備良好條件實現收入及盈利持續增長。」有關日清食品有限公司日清食品有限公司（「日清食品」，連同其附屬公司統稱「集團」；股份代號：1475）為一間在中國内地及香港知名的食品公司，主要專營優質即食麵市場，旗下眾多品牌不僅知名度高，且廣受顧客喜愛。集團於1984年正式於香港設立營業據點並為香港最大的即食麵公司。集團主要生產及銷售兩個核心企業品牌「日清」及「公仔」，以及多元化的家庭食品品牌組合，出品具標誌性和優質的即食麵、優質冷凍食品（包括冷凍點心及冷凍麵條）並銷售和分銷其他食品及飲料產品（包括蒸煮袋裝產品、零食、礦泉水、醬料及蔬菜產品）。集團五個旗艦品牌「合味道」、「出前一丁」、「公仔麵」、「公仔點心」及「福」在香港亦是其各自食品類別中最受歡迎的選擇。中國内地市場方面，集團以創新技術推出「ECO杯」概念，銷售活動主要集中在中國内地的一線及二線城市。此外，日清食品在其他地區開展業務，包括越南、台灣、韓國及澳洲市場。日清食品被納入5項恒生指數，包括恒生綜合指數、恒生綜合小型股指數、恒生綜合行業指數-必需性消費、恒生港股通消費行業指數和恒生港股通食品飲料消費指數。日清食品現可通過滬港通及深港通下港股通進行交易。詳情請瀏覽www.nissingroup.com.hk。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

 Financial HighlightsFor the Year Ended 31 December 2025(HK$ million)20252024ChangeRevenue 4,001.13,811.9+ 5.0%Gross Profit 1,385.11,312.1+ 5.6%Gross Profit margin34.6%34.4%+ 0.2ppProfit attributable to owners of the Company 331.4201.0+ 64.9%Net profit margin 8.3%5.3%+ 3.0ppAdjusted EBITDA  622.8612.5+ 1.7%Earnings per share (HK cents) 31.7619.26+ 64.9%HONG KONG, Mar 26 , 2026 - (ACN Newswire via SeaPRwire.com) – Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) today announced its annual results for the year ended 31 December 2025.The Group’s revenue increased by 5.0% year-on-year from HK$3,811.9 million in 2024 to HK$4,001.1 million in 2025, driven by the continued growth of the core instant noodles business, improved consumer sentiment in the Chinese Mainland, and increased demand in overseas markets. Gross profit increased by 5.6% from HK$1,312.1 million in 2024 to HK$1,385.1 million in 2025. Gross profit margin slightly increased by 0.2 percentage points from 34.4% in 2024 to 34.6% in 2025 due to a more favourable sales mix and the Group’s continued implementation of cost efficiency initiatives, which effectively absorbed cost pressure and supported margin improvement.Profit attributable to owners of the Company increased significantly by 64.9% year-on-year to HK$331.4 million, representing a net profit margin of 8.3% for the year. Profit and profitability improved substantially over the year, owing to enhanced operational efficiency and the absence of non-cash charges related to asset impairment losses recognised for the year ended 31 December 2024. The Group’s basic earnings per share increased to 31.76 HK cents for the year. At the Adjusted EBITDA level, the Group recorded an increase of 1.7% from HK$612.5 million in 2024 to HK$622.8 million in 2025, representing an Adjusted EBITDA margin of 15.6% for the year (2024: 16.1%). The Board recommends the payment of a final dividend of 15.88 HK cents per share, representing a dividend payout ratio of 50.0%.Review & Prospects by Business RegionDuring the year under review, revenue from the Hong Kong and other regions operations increased by 7.7% to HK$1,658.7 million, mainly attributable to the steady performance of the instant noodles business in Hong Kong and increased demand in other regions. Segment results rose by 16.1% to HK$152.8 million, driven by continued sales expansion in the premium instant noodles category. Meanwhile, revenue from the Chinese Mainland operations increased moderately by 3.1% to HK$2,342.4 million for the year, with segment results rose by 3.5% to HK$339.9 million, mainly attributable to ongoing efforts to expand sales in inland areas and the sustained sales momentum in the Chinese Mainland.In Hong Kong, the Company continued to enrich its instant noodle portfolio with new SKUs, including Cup Noodles Regular Cup Kyoto Tori Paitan Flavour Instant Noodle and Donbei Meat Broth Flavour Cup Udon (Instant Noodle). To boost sales and consumer engagement, Cup Noodles and Demae Iccho partnered with the virtual singer “Hatsune Miku”. The Company also enhanced its digital marketing in catering channels through a WeChat mini programme. In line with its premiumisation strategy for its frozen food business, the Company launched the Nissin The Chef’s Signature series to cater to consumers seeking elevated home culinary experiences. Meanwhile, the Company continued to broaden its non-noodle portfolio, strengthening its beverage line with seasonal products and expanding the Crisp Choco snack line with a new bite-sized mini version. Hong Kong-made Nissin Granola and fresh-cut vegetable continued to appeal to health-conscious consumers, reinforcing the Company’s commitment to health, wellness and nutrition.For its overseas markets, the Group pursued strategic market expansion and brand enhancement, achieving significant progress. In Vietnam, which remained one of Southeast Asia’s fastest-growing economies, the Company capitalised on strong consumer demand by expanding its sales and distribution channels into modern retail and targeting the youth segment with new products. In Taiwan, the establishment of a wholly-owned subsidiary has provided clearer sales direction and enhanced support to local partners, contributing to sales momentum and long-term business growth. In Korea, the business achieved a solid performance, leveraging the global popularity of K-content and Nissin's international sales network to expand its Gaemi Food Co. Ltd. (“Gaemi Food”) confectionery products into new overseas markets. Meanwhile, in Australia, the Company deepened the operational integration of ABC Pastry Holdings Pty Ltd (“ABC Pastry”) while also broadening its sales network for instant noodle products by capitalising on the growing interest in Asian cuisines across both mainstream and Asian retail channels.In the Chinese Mainland, the Company delivered a solid performance, driven by the volume expansion of its instant noodle business and strategic efforts to expand its geographical footprint into inland regions. To enhance consumer engagement and brand awareness, promotional activities were intensified through increased in-store food tasting, digital marketing on platforms such as the WeChat mini program, and a high-profile collaboration with the Japanese virtual singer “Hatsune Miku”. As part of its premiumisation strategy, the Company enriched its product offerings with new launches such as the Nissin Donbei Kitsune Cup Udon (Instant Noodle). The non-noodle business also demonstrated positive development; the distribution business broadened its portfolio with new premium imported products, including European bottled water, Japanese carbonated beverages, and Japanese chocolate and cookies, while the snack business performed well thanks to its potato chips and festive offerings such as the limited-edition Crisp Choco.Demonstrating a strong commitment to mid- to long-term growth, the Group acquired land use rights of two land parcels in Zhuhai at an aggregate consideration of RMB30.68 million during the year. The Group intends to invest over RMB240 million in acquiring the Land Parcels, constructing new buildings, and installing new production lines.Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “We are cautiously optimistic about our growth prospects as we continue to focus on cost control and operational efficiency. The global economy faces an uneven recovery due to geopolitical tensions and supply chain restructuring due to rising trade protectionism. Against this backdrop, we remain committed to continuous product upgrades and execution capabilities in markets where we see clear and sustainable demand. In Hong Kong, government initiatives are expected to underpin the economy and household spending, providing a more favourable environment for the continued premiumisation of our product portfolio. The Chinese Mainland offers significant opportunities with its growing middle class, while Vietnam's thriving retail sector and Korea's focus on health support our strategies. Additionally, the rising demand for high-quality frozen foods in Australia presents valuable growth potential.By leveraging our premiumisation and diversification strategies, we strengthen our competitiveness across these regions. With a solid financial position, cash generation, and strong brand recognition, we are well-positioned for sustained revenue and earnings growth over the medium to long term.”About Nissin Foods Company LimitedNissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and Mainland China, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN” and “DOLL” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho ”, “Doll Instant Noodle”, “Doll Dim Sum” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Mainland China market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first-and second-tier cities. In addition, Nissin Foods operates business in other regions including Vietnam, Taiwan, Korea and Australia markets.Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Consumer Staples Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 3月25日，朝雲集團（6601.HK）發佈2025年度業績報告：營收同比增長9.2%，純利同比增長10.3%，毛利率同比提升3.5個百分點，寵物業務營收增長74.3%，線上渠道營收增長30.2%，盈利能力持續提升疊加強勁現金流，持續5年高額派息80%，股息率超6%，高分紅現金奶牛屬性凸顯。營收純利連續3年增長，持續5年高額派息回饋股東過往財報顯示，朝雲集團堅持高質量、可持續、穩利潤發展原則，營收純利連續3年增長。得益於技術創新高毛利大單品矩陣及渠道結構優化，疊加供應鏈運營效率提升及成本管理措施落實，推動整體毛利同比提升3.5個百分點，盈利能力持續攀升，打破消費行業"增長見頂""只賺吆喝不賺錢"的質疑。"穩利增長+真金回饋"是朝雲給投資者最核心的安全感：連續5年高額派息80%，股息率維持超6%，將持續盈利轉化為實在的股東利益。截至2025年末，集團現金儲備超28.4億元，現金流持續強勁，"可持續、穩利潤、高派息、強現金"的組合讓朝雲成為當下市場最稀缺的安全投資標的。寵物營收猛增74.3%，自有品牌及新物種門店雙引擎驅動整體業績穩利增長下，寵物業務成為朝雲25年的增長黑馬：全年營收同比暴漲74.3%，毛利率同比增加5.3個百分點，展現極強成長性和盈利能力。高速增長源於自有品牌及新物種門店的雙擎驅動：一方面，倔強家族等自有品牌產品在門店銷售占比超30%，高複購爆品矩陣精准契合養寵人群需求；另一方面，線下跳出傳統寵物店模式，打造"貓咖飲品+商品零售+洗護服務+活體銷售"的消費一體化閉環，門店升級兼具療愈價值與社交空間屬性，滿足當下消費者對體驗式、社交化消費的升級需求，米樂乖乖、爪爪門店更是登頂多地美團、大眾點評好評榜，雙雙成為美團2025年度十佳影響力品牌。家居護理業務穩坐龍頭，連續11年市占第一作為集團壓艙石，家居護理業務龍頭地位穩固，殺蟲驅蚊品類連續11年保持行業市占第一，潔廁品類市占第一，營收同比增長5%。高端天然賽道佈局成效顯著，用創新核心產品競爭力構建護城河，毛利率同比提升2.9個百分點。階段完成河北康達的戰略收購，實現中國南北區域市場優勢互補，進一步夯實家居護理領先優勢，提升增長後勁。線上營收大增30.2%，盈利能力持續提升2025年朝雲渠道結構持續優化：線上構建淘系、京東、拼多多、內容電商4大超億元渠道，提升便攜驅蚊、香氛、家清、寵食等高複購趨勢品的銷售占比，通過自有團隊精細化運營，持續提升投產，25年營收同比增長30.2%，毛利率提升5.5個百分點，真正實現依靠產品力和運營效率賺錢。線下渠道推動全品類分銷，提升終端市場覆蓋廣度與深度，搶抓即時零售增量市場，鞏固市場領導地位。同時，供應鏈改革成效顯著，通過自動化改造、集采優化等措施進一步夯實成本優勢，提升全渠道盈利。未來朝雲集團將堅持高質量、可持續、穩利潤發展原則，保持強勁的現金流、持續提升盈利能力、持續落實高額派息政策。家居護理佈局高價值賽道，提毛利、拓增量，通過兼併購進一步鞏固領導地位，寵物高質量拓店，提升單店盈利，線上線下協同打造爆品矩陣。優化線上渠道組合打造更多億元渠道，通過核心產品競爭力鞏固領先地位和護城河。加強技術創新，持續打造高毛利大單品矩陣，為公司注入可持續發展動力，為股東創造更大價值。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 大消費板塊承壓行業整體尋求破局的背景下，"鏟屎官經濟"熱度不減，走出獨立行情。朝雲集團（6601.HK）2025年度財報證明：搞不定鏟屎官的龍頭，不是好的快消龍頭：營收純利連續3年增長，寵物業務營收暴增74.3%，成為鏟屎官和投資者共同的心頭好。一、寵物業務猛增74.3%，小貓變猛虎鏟屎官們的心已被朝雲牢牢抓住：2025 年的寵物業務營收暴增 74.3%達2.22億元，毛利率同比提升5.3個百分點，從2019年百萬級營收躍升至2025年億元量級，年複合增長率高達124%，真正完成"新手小貓"到"業績猛虎"的蛻變。朝雲寵物爆發並非偶然，而是自有品牌與新物種門店雙擎驅動的必然結果：自有品牌破圈：技術創新打造如寵物生鮮包等爆品矩陣，貓砂盆清潔泡泡等潛力單品快速成長，精准擊中鏟屎官對"高品質、好體驗"的需求，主導貓砂行業標準、新型寵物酥化糧標準編修，用技術壁壘築牢護城河。新物種門店打造從產品到服務消費一體化閉環： 全國73家自營店升級成寵物友好空間，跑通"飲品+沉浸式寵物體驗"模型，高顏值飲品引流，沉浸式貓咖體驗留客，商品零售變現，一站打通流量、體驗和複購，解決傳統寵物店"獲客難、客單波動大"的痛點。旗下米樂乖乖13家門店獲大眾點評區域好評榜第一，米樂、爪爪同時成為美團2025年度十佳影響力品牌。全生態佈局築牢護城河：從"研發、生產、銷售"，到"寵物食品、用品自有品牌打造"，再到下游"新物種門店"，朝雲圍繞寵物全生命週期構建生態閉環，以對寵物安全友好為初心，把"鏟屎官經濟"的流量變成持續複購。二、營收純利連續3年增長，保持5年高額派息寵物業務猛虎出山，朝雲"老家"穩如泰山，家居護理營收同比增長5%至17.15億，殺蟲驅蚊產品連續11年市占第一、潔廁市占第一穩坐龍頭。2025年集團業績表現亮眼：整體營收達19.9億元，同比增長9.2%，純利2.2億元，同比增長10.3%，毛利率同比提升3.5個百分點，均實現連續3年增長。作為能賺會花的股東友好型公司，朝雲堅持與股東共享紅利，保持5年高額派息80%，股息率超6%。截至2025年底，集團賬上還有28.4億元現金儲備，強勁的現金流不僅為未來持續派息築牢根基，也為業務擴張和併購預留了彈藥。從家居護理龍頭到寵物業務爆發式增長，再到高額派息穩定回報，朝雲有業績韌性、有現金流、有穩定派息；從未來看，寵物賽道的爆發式增長、家居護理的高端化升級、外延併購帶來的規模效應，都是看得見的增長引擎，而朝雲這只"猛虎"才剛剛出山。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 3月25日，小鵬匯天 X3-F（陸地航母）飛行汽車所搭載的頂流圓柱電池系統在中創新航成都工廠量產下線。據了解，此次下線的動力電池產品應用了中創新航全球首創的「頂流圓柱」電池技術。該「頂流」高能飛行電池，能量密度達360Wh/kg，是行業能量密度最高的固液混合圓柱電池，在高安全性、高功率密度與高能量密度之間實現了卓越平衡，嚴格滿足航空級安全標準，將配套應用於小鵬匯天多款飛行汽車。雙方合作始於2022年，中創新航助力小鵬匯天完成了全球首個電動垂起飛行汽車的首飛。在歷經了一系列嚴苛驗證之後，中創新航電池產品的可靠性得到了充分檢驗。以此為契機，中創新航組織優勢科研力量，重點佈局下一代「頂流圓柱」電池，針對一系列基礎科學和技術難題組織了專項攻關，並牽頭聯合小鵬匯天等優勢單位獲得國家重點研發計劃項目支持，切實推動了相應航空動力電池本徵安全與高比能技術的國際領先。基於此，雙方於2025年4月簽署深化戰略合作協議，確立下一代機型的獨家供應關係。從牽頭國家重點研發計劃攻關「頂流圓柱」技術，到此次飛行汽車電池率先實現量產落地，中創新航在前瞻性新興賽道的佈局正加速兌現。多元化應用場景中的商業化能力的持續夯實，為其在下一代能源技術競爭中打開了新的增長空間。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 26 , 2026 - (ACN Newswire via SeaPRwire.com) – On March 25, CALB (03931.HK) rolled off the production line of the advanced R46 cylindrical battery system at its Chengdu factory, set to power the XPENG ARIDGE X3-F (Land Aircraft Carrier) flying car. According to sources, this power battery product utilizes CALB’s first-unveiled R46 cylindrical battery system technology. Boasting an energy density of 360Wh/kg, the battery stands as the highest-density solid-liquid hybrid cylindrical battery in the industry. It achieves an exceptional balance between high safety, high power density, and high energy density, and will be equipped in several of ARIDGE’s flying car models.The partnership between the two parties began in 2022, with CALB assisting ARIDGE in completing the world’s maiden flight of an electric vertical take-off and landing (eVTOL) flying car. Following a series of rigorous validations, the reliability of CALB’s battery products has been fully verified. Building on this momentum, CALB assembled a team of top researchers to focus on the next-generation advanced R46 cylindrical battery system, tasked with addressing a range of scientific and technological challenges. Furthermore, by taking the lead in collaborating with leading institutions including ARIDGE, the company has been awarded support from the National Key R&D Program Project, further positioning the technologies at the forefront of global innovation in intrinsic safety and high-specific-energy aviation power batteries. Consequently, the two parties have signed a deepened strategic cooperation agreement in April 2025, establishing an exclusive supply relationship for next-generation models.From leading the National Key R&D Program focused on advanced R46 cylindrical battery system technology to achieving mass production of flying car batteries, CALB is accelerating its expansion into forward-looking emerging sectors. The company’s commercialization capabilities across diversified application scenarios continue to strengthen, opening new growth opportunities in the competition for next-generation energy technologies. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TransNusa To Operate Additional Frequencies for Both Singapore-Jakarta and Singapore-Bali Routes- Additional frequencies respond to strong demand for travel between Indonesia and Singapore while strengthening regional connectivity- Both routes received additional scheduled flight slots, providing TransNusa passengers options for day travel- TransNusa increases its minimum baggage allowance to 20kgs, in addition to the 7kg hand carry for it’s minimum package bundle, SEAT, and increased minimum baggage allowance to 30kgs for its highest bundle, Flexi-ProJAKARTA, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - PT TransNusa Aviation Mandiri (TransNusa) today announced the launch of additional scheduled flights between Jakarta and Singapore as well as Jakarta and Bali, further strengthening connectivity between two of Southeast Asia’s paramount business and tourism travel hubs.TransNusa Group Chief Executive Officer, Datuk Bernard Francis said that the additional scheduled flight between Soekarno–Hatta International Airport in Jakarta and Singapore Changi Airport will start on April 17 while the additional flight from Gusti Ngurah Rai International Airport in Bali to Changi Airport will start on May 2. Sale of tickets for both additional scheduled flights started on March 17 and can be bought directly from transnusa.co.id or on any main online travel agency platform.The additional flights are part of the TransNusa’s broader strategy to expand regional connectivity and respond to the growing demand for travel between Indonesia and Singapore—two markets with strong economic, cultural, and tourism ties.“Singapore is one of the region’s vital aviation and commercial hub, and these additional flights will provide travellers with greater flexibility while supporting trade and tourism between the two countries,” Datuk Bernard added.“The Jakarta–Singapore corridor is one of the busiest international routes in the region, serving millions of travellers each year. By increasing capacity on this route, we aim to provide a more seamless connections for passengers traveling across Southeast Asia and beyond,” Datuk Bernard stressed, adding that TransNusa’s passengers will benefit from improved scheduling options, allowing for easier same-day connections to a wider network of destinations.“Our goal is to continue improving accessibility across Southeast Asia by increasing frequencies on high-demand routes,” explained Datuk Bernard.Flight DetailsTransNusa’s additional scheduled flight, 8B 155, will depart Jakarta at 07.45pm from Soekarno-Hatta International Airport in Jakarta and arrive at the Singapore Changi Airport at 10.25pm. The flight, 8B 156, will depart Singapore Changi Airport at 11.20pm and arrive at Soekarno-Hatta International Airport in Jakarta at 12.10am.With the launch of this news additional Frequency, TransNusa will be operating three daily flights from Jakarta to Singapore effective April 17, 2026.On the Bali-Singapore route, TransNusa's new scheduled flight, 8B 553, will depart the Gusti Ngurah Rai International Airport at 10.20am and arrive at Changi Airport at 01.15pm. Meanwhile, TransNusa’s flight, 8B 554, will depart Changi Airport at 02.15pm and arrive back at the Gusti Ngurah Rai International Airport in Bali at 05.55pm.TransNusa will be utilising its Airbus A320 for both the international routes.TransNusa, which aims to ensure its passengers travel with ease and comfort, has configured its A320 aircrafts with a 174-seat configuration, which allows for passengers to enjoy about 30 inches of legroom, comparable to the experience passengers would get in a full-service airline."We are committed to providing affordable and competitive ticket prices, while still providing premium services to our customers,” stressed Datuk Bernard.For its international flights, TransNusa not only provides premium services with competitive ticket prices, but the airline also has attractive product bundles called SEAT, SEAT-PLUS and FLEXI-PRO."Our SEAT passengers will now enjoy check-in baggage of 20kgs,” Datuk Bernard said, explaining that the baggage offering was over and above the 7kgs limit offered as a passenger’s hand carry.“For the highest package, FLEXI-PRO, we have increased our baggage allowance to 30kgs, free to choose seats, free food, and drinks, and priority boarding. In addition, TransNusa also provides its FLEXI-PRO passengers with the flexibility to change their flight schedule without restrictions and obtain refund when needed,” concluded Datuk Bernard.About TransNusaTransNusa Airline, is a Premium Service Carrier. In February 2024, the airline rebranded itself to a Premium Service Carrier in line with its upgraded aircrafts that offers better comfort as well as based on the flexibility and quality of the services offered. TransNusa, which received its AOC certification on 9th September 2022, launch its first three A320 operations on 6th October, 14th October and 12th December, 2022.In 2023, TransNusa introduced a new business model making it the first Premium Service Carrier in the Asia Pacific region. TransNusa introduced its first international flight on 14th April, 2023. The airline is currently based in Jakarta and Bali.On the international front, TransNusa flies to Singapore, Guangzhou, Kuala Lumpur, Perth, Shanghai, and Shenzhen. The airline became the second Indonesian airline to fly to China and the first Indonesian airline to launch a Premium Service Carrier business model. Passengers can book their flights on the TransNusa website at www.transnusa.co.id, through any secure online travel agent, through authorized travel agents in Singapore and Indonesia.Primary International Media ContactTrina Thomas RajMobile: +6012 4992672E-mail: trina@myqaseh.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CLEVELAND, Ohio, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, announced the implementation of a transportation surcharge to address continued cost escalation across the Americas freight and logistics market. Beginning April 1, 2026, a $350 per delivery surcharge will apply to all shipments.The freight and logistics market continues to experience elevated costs driven by rising diesel prices, evolving regulatory requirements affecting driver availability, tighter trucking capacity, and increasing operating expenses across the logistics sector. Industry forecasts indicate these pressures will persist for the foreseeable future."Maintaining reliable service for our customers requires us to adapt to sustained shifts in the transportation landscape," said Tom Kelly, Formerra CEO. "This surcharge is necessary to address these industrywide cost pressures that are outside of our control while continuing to provide the high service levels customers expect from Formerra."Customers should contact their Formerra representative for more information.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.Media ContactJackie MorrisFormerraMarketing Communications Managerjackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

俄亥俄州克利夫蘭, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 高性能材料分銷領域的領導者 Formerra 宣布將實施運輸附加費，以因應美洲貨運與物流市場持續攀升的成本。自 2026 年 4 月 1 日起，所有貨件將適用每筆運送 350 美元的附加費。受柴油價格上漲、影響司機供應的監管要求變化、卡車運輸運力趨緊，以及物流業整體營運成本攀升等因素驅動，貨運與物流市場持續面臨成本高企的困境。業界預測顯示，這些壓力在可預見的未來將持續存在。「為維持對客戶的可靠服務，我們必須適應運輸環境的持續變革，」Formerra 執行長 Tom Kelly 表示。「這項附加費是必要的，旨在應對這些超出我們控制範圍的業界成本壓力，同時持續提供客戶對 Formerra 所期待的高水準服務。」客戶如需更多資訊，請聯繫您的 Formerra 業務代表。關於 FormerraFormerra 是工程材料領域的頂尖分銷商，串聯全球領先的聚合物生產商與醫療保健、消費品、工業及移動出行市場中的數千家原始設備製造商（OEM）和品牌所有者。憑藉技術與商業專業知識，Formerra 融合了產品組合深度、供應鏈實力、產業知識、服務品質、領先的電子商務能力以及創新思維，形成獨特的優勢組合。Formerra 經驗豐富的團隊協助各產業客戶以嶄新且更佳的方式進行產品設計、選材、加工與開發，從而提升產品性能、生產力、可靠性及永續性。欲了解更多資訊，請造訪 www.formerra.com 。媒體聯絡人Jackie MorrisFormerra行銷傳播經理 jackie.morris@formerra.com+1 630-972-3144消息來源：Formerra Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Toronto, ON, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - Aleen Inc. (CSE: ALEN-U), a digital wellness company, has introduced a new data layer within its Personal Wellness Account, designed to enhance how its AI assistant interprets and structures wellness data.As part of its ongoing product development, Aleen Inc. has implemented a biomarker extraction approach that enables the system to process user-provided data and identify key indicators in a more structured way. This includes the use of a dedicated AI agent that processes documents page by page and extracts relevant biomarkers from wellness data sources.In addition to extraction, Aleen Inc. is developing a standardized structure for each biomarker, including its name, value, unit of measurement, and reference range. These structured data elements are now reflected within the Personal Wellness Account interface. Users will be able to view the total number of detected biomarkers and potential deviations directly within the file list, while a dedicated “Biomarkers” tab in the detailed view provides expanded access to the data in both table and panel formats, along with search and filtering capabilities.This development represents a step toward more structured data environments within Aleen’s ecosystem, supporting improved organization, accessibility, and interaction with wellness data. The introduction of this layer may also contribute to future enhancements in how the system identifies patterns and supports user-centered insights. This update reflects Aleen Inc.’s continued focus on building scalable data architecture and advancing its Personal Wellness Account as a structured, AI-assisted environment for working with wellness data.About Aleen Inc.Aleen Inc. operates as a digital wellness and well-being insights company. Its platform transforms personal wellness information into simple, personalized insights that promote greater self-awareness and balance in daily life. Aleen’s mission is to empower individuals with knowledge and clarity through responsible use of technology and data.For more information, visit www.aleen.ca.Forward-Looking StatementThis press release contains forward-looking statements regarding future plans and developments by Aleen Inc. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Aleen Inc. undertakes no obligation to update or revise these statements except as required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation and globalization. Revenue increased 13.02% year-on-year to RMB 31.63 billion, and net profit attributable to shareholders increased by 21.69% to RMB 7.71 billion.Innovation remained the engine of Hengrui’s growth: Innovative drug sales increased by 26.09% year-on-year to RMB 16.34 billion, contributing 58.34% to total drug sales. This was driven by a robust pipeline across therapeutic areas, with oncology products contributing RMB 13.24 billion in revenue (+18.52% YoY), and non-oncology products contributing RMB 3.10 billion in revenue (+73.36% YoY).Hengrui kept innovation at its core, with R&D expenditure reaching RMB 8.72 billion in 2025, accounting for 27.58% of total revenue, of which RMB 6.96 billion was expensed. During the year, the company secured seven approvals for Class 1 innovative drug, one for a Class 2 innovative drug, and six for new indications of marketed innovative drugs. The pace of regulatory progress accelerated with 15 NDA/BLAs accepted by the NMPA. Meanwhile, 28 drug candidates entered Phase III clinical trials, 61 progressed to Phase II, and 28 NMEs entered Phase I for the first time.The company currently has over 100 proprietary innovative products in clinical development and is conducting more than 400 clinical trials. This robust portfolio will be further supported by approximately 53 innovative product and indication approvals anticipated during 2026-2028.2025 marked another year of accelerated progress in Hengrui's global expansion. Licensing revenue rose 25.62% to RMB 3.39 billion, cementing the growing global recognition and value of the company’s innovative portfolio. During the year, the company completed five overseas business development transactions for innovative drugs with leading MNCs and biotechs, highlighted by a strategic collaboration with GSK. In parallel, the company continued to advance its self-developed assets and global regulatory efforts. Multiple innovative drugs had their first global clinical trials initiated, ranging from Phase I to III.Additionally, Hengrui successfully listed on the Hong Kong Stock Exchange, raising total gross proceeds of HK$11.4 billion (US$1.5 billion), including the over-allotment option — marking the largest pharmaceutical IPO in Hong Kong in the past five years and further strengthening its access to global capital.Looking ahead, Hengrui will continue to focus on addressing unmet clinical needs with its differentiated innovative portfolio, placing equal emphasis on independent R&D and open collaboration to expand access to innovative drugs for patients worldwide.About Hengrui PharmaHengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology.Forward-Looking StatementsThis press release contains forward-looking statements, including statements about the company's future growth prospects and pipeline potential. These statements are based on current expectations and assumptions and do not guarantee future performance. Actual results, developments, and business decisions may differ materially from these forward-looking statements. All information in this press release is as of the date of this press release, and Hengrui undertakes no duty to update such information unless required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月25日 - (亞太商訊 via SeaPRwire.com) - 3月25日，恒瑞醫藥發佈2025年年度報告。報告期內，公司堅持「科技創新+國際化」雙輪驅動戰略，實現業績持續增長，營收和淨利均再創新高。全年實現營業收入人民幣316.29億元，同比增長13.02%；歸屬於上市公司股東的淨利潤77.11億元，同比增長21.69%；歸屬於上市公司股東的扣除非經常性損益的淨利潤74.13億元，同比增長20.00%。創新藥銷售收入163.42億元，同比增長26.09%，佔藥品銷售收入比重達58.34%；對外許可收入33.92億元，同比增長25.62%。在業績持續增長的同時，公司保持高强度研發投入，全年累計研發投入87.24億元，佔營業收入的27.58%，其中費用化研發投入69.61億元，為發展築牢創新根基。創新成果轉化高效賦能，創新藥銷售引領業績增長創新藥銷售收入中，抗腫瘤産品收入132.40億元，同比增長18.52%，佔整體創新藥銷售收入的81.02%。醫保內創新藥瑞維魯胺（二代AR拮抗劑）、達爾西利（CDK4/6抑制劑）精準定位未被滿足的臨床需求，優異的臨床數據在診療實踐中得到廣泛驗證，銷售收入繼續保持强勁增長。氟唑帕利（PARP抑制劑）、海曲泊帕（TPO受體激動劑）等上市較早的創新藥，隨著新適應症的持續獲批或上市後研究循證醫學證據的逐步積累，持續為公司銷售收入注入穩定增量。伊立替康脂質體（TOP1）、瑞康曲妥珠單抗（HER2 ADC）等産品雖處於商業化初期，報告期內尚未納入醫保，但憑藉針對特定患者的明確療效優勢，通過高效的上市前準備與市場准入策略，有力驅動了産品前期的快速放量。創新藥銷售收入中，非腫瘤産品實現收入31.02億元，同比增長73.36%，佔整體創新藥銷售收入的18.98%。恒格列淨（SGLT2抑制劑）、瑞馬唑侖（GABAa受體激動劑）等醫保內産品通過臨床優勢的有效傳遞，實現較快增長。新藥新適應症持續獲批，三年內約53款創新成果蓄勢待發2025年，公司持續加大創新力度。報告期內，公司上海創新研發中心正式啓用，進一步完善公司研發體系。公司持續建設行業領先的新技術平台，加强源頭創新。報告期內，公司不斷完善已建立成熟的ADC、雙/多抗、蛋白降解劑、小核酸藥物、口服多肽、PROTAC/分子膠/RIPTAC等技術平台，初步建成新分子模式平台。同時，恒瑞大力發展人工智能藥物發現（AIDD），全面賦能藥物研發的創新與迭代。公司已形成行業領先且高度差異化的創新産品矩陣。目前，公司已在中國獲批上市24款1類創新藥、5款2類新藥，另有100多個自主創新産品正在臨床開發，400餘項臨床試驗在國內外開展。2025年，公司（含報表內子公司）7款1類創新藥獲批上市，包括注射用瑞卡西單抗、硫酸艾瑪昔替尼片、瑞格列汀二甲雙胍片(I)(II)、注射用瑞康曲妥珠單抗、蘋果酸法米替尼膠囊、注射用磷羅拉匹坦帕洛諾司瓊、澤美妥司他片等； 1款2類創新藥獲批上市，6個已獲批創新藥的新適應症獲批上市，涵蓋腫瘤、代謝、心血管、免疫、神經科學等疾病領域。報告期內公司研發管綫顯著進展，共有15項上市申請獲NMPA受理，28項臨床推進至III期，61項臨床推進至II期，28項創新産品首次推進至臨床I期。2025年，公司取得藥物臨床批件180個；獲得CDE突破性治療品種認定8項，優先審評品種認定2項。此外，2025年公司招募了22,000餘名參與者參加臨床研究，自有的臨床開發實力使公司能夠高效推進産品的監管評審進度。專利申請和維持工作順利開展。報告期內，獲得大中華地區授權76件、國外授權209件。截至報告期末，擁有大中華區授權發明專利986件，歐美日等國外授權專利1,021件。2025年，恒瑞醫藥共有20款産品／適應症通過新版國家醫保目錄調整，其中10款産品首次進入醫保，不斷提升優質藥物的可及性與可負擔性，也有助於加速産品放量，提升市場份額，進一步鞏固公司在創新藥領域的領先地位。未來成長性方面，公司增長潛力有望進一步釋放。根據公告，2026-2028年預計約有53項創新成果獲批上市。其中，新品上市方面，具備同類最佳潛力的GLP-1/GIP雙受體激動劑HRS9531用於超重／肥胖有望獲批。在新適應症獲批方面，瑞康曲妥珠單抗有望獲批用於HER2陽性結直腸癌、HER2陽性乳腺癌一綫治療等多個新適應症。國際化提速，BD成業績增長新引擎雄厚的創新研發實力，為公司高水平的國際化合作奠定了堅實基礎。2025年，恒瑞醫藥BD合作模式持續創新，共達成5筆創新藥海外業務拓展交易。其中與GSK達成戰略聯盟尤為矚目：雙方共同開發包括PDE3/4抑制劑HRS-9821在內的至多12款創新藥，恒瑞獲得5億美元首付款，潛在總金額約120億美元的選擇權行使費和里程碑付款及相應的銷售提成，彰顯對恒瑞創新平台與研發實力的深度認可。與MSD就Lp(a)抑制劑HRS-5346達成大中華區外獨家許可，2億美元首付及最高17.7億美元里程碑付款，進一步驗證全球競爭力。此外，口服GnRH拮抗劑SHR7280中國大陸商業化權益授權Merck KGaA，Myosin小分子抑制劑HRS-1893以NewCo模式授權Braveheart Bio，瑞康曲妥珠單抗部分國際市場權益授權Glenmark。自2023年起公司已完成12筆海外業務拓展交易，包括對外許可、NewCo和戰略聯盟等不同模式，潛在總交易價值超過270億美元。這一系列活躍的BD交易，正加速推動恒瑞創新藥的全球價值兌現。與此同時，恒瑞也在積極推進海外自主開發及註册。報告期內，公司新開設美國波士頓臨床研發及合作中心。目前，公司在亞洲、歐美及澳大利亞設立15個研發中心，報告期內多個創新藥啟動首項海外臨床試驗。此外，報告期內，HER2 ADC創新藥瑞康曲妥珠單抗聯合阿得貝利和化療用於胃癌或胃食管結合部腺癌獲美國FDA孤兒藥資格認定。目前公司共有5款創新藥獲FDA孤兒藥資格認定，4款ADC産品獲FDA快速通道資格認定。此外，報告期內公司成功登陸港交所實現「A+H」上市，募集資金113.74億港元，為近5年港股醫藥板塊最大IPO，國際化邁向新的里程碑。2025年，公司積極探索創新治療方案，向世界展現「中國藥」的臨床價值。報告期內已有與公司産品相關的381項重要研究成果獲得國際認可。相繼在CA（臨床醫師癌症雜誌）、The Lancet（柳葉刀）、JAMA（美國醫學會雜誌）等全球頂級期刊發表，累計影響因子達3,159分，包括18篇重磅研究論文（腫瘤領域影響因子≥30分、非腫瘤領域影響因子≥20分的國際期刊）。公司在全球學術舞台的參與維度也再上新台階。腫瘤領域，2025年有72項、46項研究分別入選ASCO年會、ESMO年會，並首次以展台形式登陸ESMO；非腫瘤領域多項成果被美國糖尿病協會（ADA）年會、美國皮膚科學會（AAD）、歐洲腎臟協會大會（ERA）等國際會議錄用為口頭報告。構建全球化人才梯隊，運營管理全面升級國際化戰略的深化，離不開全球化組織能力的支撑。2025年，公司深化引智育才，構建全球化人才梯隊。聘請馮佶女士加盟並出任公司總裁，强化全球戰略領導力；聘請朱國新先生為公司高級副總裁、全球早研負責人，强化管綫的前瞻佈局與源頭創新；聘請尹航先生為公司副總裁、腫瘤事業部總經理，持續强化腫瘤領域競爭力；聘請Yu Liu先生為國際首席醫學官，負責推動在美國及中國以外地區的臨床開發工作；聘請Karen Atkin女士擔任國際商業和組合策略負責人，進一步加强海外商業拓展。同時，通過「全球精英計劃」廣泛吸引來自全球頂尖院校與科研機構的優秀學生及青年學者加入。內部培養方面，針對不同層級的關鍵人才，系統性實施「中高層高潛人才400發展項目」、「新晋管理者訓練營」及「恒瑞領導力峰會」等培養計劃，全力打造專業、年輕、國際化的一流人才梯隊。公司持續强化戰略與組織適配，2025年新成立生物製藥事業部（BBU），與原有腫瘤事業部（OBU）齊頭並進，通過組織升級來提升領先的商業化能力。公司形成商業卓越、市場營銷、醫學事務、中央及省級銷售管理、中央及省級市場准入等互補職能體系賦能專業銷售隊伍。公司建立了廣泛而深入的全渠道覆蓋網絡。目前，公司的銷售網絡遍佈全國超過25,000家醫院及超過200,000家綫下零售藥店。此外，公司設立基層廣闊市場架構，根據市場潛力和産品屬性，對廣闊市場佈局進行升級。截至目前，公司社區終端覆蓋已突破2,500家，累計開展學術活動覆蓋醫生2萬人次，基層品牌影響力顯著提升。深化政産學研融合，踐行可持續承諾為進一步强化公司在生物醫藥領域的基礎研究能力，公司積極推動政産學研聯動，與國家自然科學基金委員會聯合成立「國家自然科學基金民營企業創新發展聯合基金」，總計1.32億元，重點圍繞腫瘤、代謝性疾病等方向開展基礎或應用基礎研究。此外，與中國科技發展基金會簽署戰略合作備忘錄，將出資1億元人民幣，用於資助科技創新、資源賦能、人才培育、國際交流等七大領域的項目，携手推動科技創新和産業創新深度融合。同時，作為中國醫藥創新的領軍企業，恒瑞醫藥始終重視履行社會責任，深度踐行可持續發展理念。2025年11月，香港大埔宏福苑發生嚴重火災，災情引發社會各界深深關切。恒瑞醫藥宣佈緊急捐贈1000萬港元，用於緊急救援以及災後重建等工作。憑藉在醫藥創新、合規運營、綠色發展及社會責任等領域的優異表現，恒瑞醫藥在國際權威指數機構明晟（MSCI）ESG評級躍升至「AA」級，躋身全球製藥行業前列。憑藉創新、國際化高質量發展的成果，恒瑞醫藥屢獲國內外權威認可。連續7年上榜美國製藥經理人雜誌公佈的全球製藥企業TOP50榜單；根據2025年Citeline 發佈的管綫規模排名，公司自研管綫規模位居全球第二； 成功躋身財富中文網發佈的2025年《財富》中國500强； 海曲泊帕乙醇胺片（恒曲®）專利榮獲中國專利金獎；恒瑞醫藥還連續5年榮膺「中國傑出僱主」認證，人力資源管理領域成就再獲肯定。未來，恒瑞醫藥將繼續秉持「科技創新+國際化」雙輪驅動戰略，深耕臨床未滿足需求，打造差異化創新産品；堅持自主研發與開放合作並重，為全球患者帶來更多、更好的治療選擇。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com